Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Lung Cancer

Retrieve available abstracts of 466 articles:
HTML format

Single Articles

    October 2021
  1. MONDACA S, Lebow ES, Namakydoust A, Razavi P, et al
    Corrigendum to "Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions" [Lung Cancer 159 (2021) 66-73].
    Lung Cancer. 2021 Oct 5. pii: S0169-5002(21)00552.

    September 2021
  2. MODY GN, Stover AM, Wang M, King-Kallimanis BL, et al
    Electronic patient-reported outcomes monitoring during lung cancer chemotherapy: A nested cohort within the PRO-TECT pragmatic trial (AFT-39).
    Lung Cancer. 2021;162:1-8.
    PubMed     Abstract available

  3. LI M, Zhang C, Deng S, Li L, et al
    Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer.
    Lung Cancer. 2021;162:16-22.
    PubMed     Abstract available

  4. JOOSTEN PJM, de Langen AJ, van der Noort V, Monkhorst K, et al
    The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
    Lung Cancer. 2021;161:141-151.
    PubMed     Abstract available

  5. TU Z, Li C, Tian T, Chen Q, et al
    A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion.
    Lung Cancer. 2021;161:114-121.
    PubMed     Abstract available

  6. KRAMER T, Annema JT
    Advanced bronchoscopic techniques for the diagnosis and treatment of peripheral lung cancer.
    Lung Cancer. 2021;161:152-162.
    PubMed     Abstract available

  7. MAAT APWM, Cornelissen R, Bogers AJJC, Mahtab EAF, et al
    Erratum to "Letter to the Editor: Comment on 'Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions''' [Lung Cancer 159 (2021) 127].
    Lung Cancer. 2021 Sep 20. pii: S0169-5002(21)00539.

  8. BALATA H, Ruparel M, O'Dowd E, Ledson M, et al
    Analysis of the baseline performance of five UK lung cancer screening programmes.
    Lung Cancer. 2021;161:136-140.
    PubMed     Abstract available

  9. BARANY N, Rozsas A, Megyesfalvi Z, Grusch M, et al
    Clinical relevance of circulating activin A and follistatin in small cell lung cancer.
    Lung Cancer. 2021;161:128-135.
    PubMed     Abstract available

  10. AULIAC JB, Monnet I, Bizieux A, Greillier L, et al
    Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
    Lung Cancer. 2021;161:122-127.
    PubMed     Abstract available

  11. JAIRAM V, Pasha S, Soulos PR, Gross CP, et al
    Post-operative radiation therapy for non-small cell lung cancer: A comparison of radiation therapy techniques.
    Lung Cancer. 2021;161:171-179.
    PubMed     Abstract available

  12. CLARKE JM, Patel JD, Robert F, Kio EA, et al
    Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
    Lung Cancer. 2021;161:180-188.
    PubMed     Abstract available

  13. HARADA G, Santini FC, Wilhelm C, Drilon A, et al
    NTRK fusions in lung cancer: From biology to therapy.
    Lung Cancer. 2021;161:108-113.
    PubMed     Abstract available

  14. BOUDY AS, Grausz N, Selleret L, Gligorov J, et al
    Use of tyrosine kinase inhibitors during pregnancy for oncogenic-driven advanced non-small cell lung carcinoma.
    Lung Cancer. 2021;161:68-75.
    PubMed     Abstract available

  15. WINKELMAN JA, van der Woude L, Heineman DJ, Bahce I, et al
    A nationwide population-based cohort study of surgical care for patients with superior sulcus tumors: Results from the Dutch Lung Cancer Audit for Surgery (DLCA-S).
    Lung Cancer. 2021;161:42-48.
    PubMed     Abstract available

  16. SAITO G, Oya Y, Taniguchi Y, Kawachi H, et al
    Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON).
    Lung Cancer. 2021;161:86-93.
    PubMed     Abstract available

  17. CASTELLANOS SH, Pagano A, Plodkowski AJ, Girshman J, et al
    Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.
    Lung Cancer. 2021;161:60-67.
    PubMed     Abstract available

  18. ANDREANO A, Bergamaschi W, Russo AG
    Immune checkpoint inhibitors at any treatment line in advanced NSCLC: Real-world overall survival in a large Italian cohort.
    Lung Cancer. 2021;159:145-152.
    PubMed     Abstract available

  19. GAO J, Zhang L, Li Z, Wang F, et al
    UniPortal thoracoscopic pneumonectomy does not compromise perioperative and long-term survival in patients with NSCLC: A retrospective, multicenter, and propensity score matching study.
    Lung Cancer. 2021;159:135-144.
    PubMed     Abstract available

  20. Letter to the Editor: Comment on 'Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions'.
    Lung Cancer. 2021;159:127.

  21. BITTONI M, Yang JC, Shih JY, Peled N, et al
    Real-world insights into patients with advanced NSCLC and MET alterations.
    Lung Cancer. 2021;159:96-106.
    PubMed     Abstract available

  22. KIM RY, Li Y, Marmarelis ME, Vachani A, et al
    Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma.
    Lung Cancer. 2021;159:107-110.
    PubMed     Abstract available

  23. OIWA H, Aokage K, Suzuki A, Sato K, et al
    Clinicopathological, gene expression and genetic features of stage I lung adenocarcinoma with necrosis.
    Lung Cancer. 2021;159:74-83.
    PubMed     Abstract available

  24. MONDACA S, Lebow ES, Namakydoust A, Razavi P, et al
    Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
    Lung Cancer. 2021;159:66-73.
    PubMed     Abstract available

  25. SEBAN RD, Assie JB, Giroux-Leprieur E, Massiani MA, et al
    Prognostic value of inflammatory response biomarkers using peripheral blood and [18F]-FDG PET/CT in advanced NSCLC patients treated with first-line chemo- or immunotherapy.
    Lung Cancer. 2021;159:45-55.
    PubMed     Abstract available

  26. MAUCLET C, Collard P, Ghaye B, Hoton D, et al
    Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAF(V600) mutation as an acquired resistance mechanism.
    Lung Cancer. 2021;159:42-44.
    PubMed     Abstract available

  27. LAM TC, Tsang KC, Choi HC, Lee VH, et al
    Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.
    Lung Cancer. 2021;159:18-26.
    PubMed     Abstract available

  28. DEMPKE WCM, Reck M
    KEAP1/NRF2 (NFE2L2) mutations in NSCLC - Fuel for a superresistant phenotype?
    Lung Cancer. 2021;159:10-17.
    PubMed     Abstract available

  29. ZHANG J, Huang J, Li Q, Lin H, et al
    DNA and RNA sequencing revealed a complex intergenic-ALK fusion in a lung adenocarcinoma patient who responded to TKI therapy.
    Lung Cancer. 2021;159:171-174.

  30. CHANG HC, Ko PH, Chang YS, Chou PC, et al
    Acute generalized exanthematous pustulosis induced by atezolizumab in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;159:175-176.

  31. ROSSI UG, Rossi GA
    Pulmonary anatomy, pathology and treatment: What will be the artificial intelligence and deep-learning role on them?
    Lung Cancer. 2021;159:181-182.

    August 2021
  32. MORIMOTO K, Yamada T, Yokoi T, Kijima T, et al
    Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2021;161:26-33.
    PubMed     Abstract available

  33. NORO R, Igawa S, Bessho A, Hirose T, et al
    A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.
    Lung Cancer. 2021;161:49-54.
    PubMed     Abstract available

  34. NAGASAKA M, Asad MFB, Al Hallak MN, Uddin MH, et al
    Impact of XPO1 mutations on survival outcomes in metastatic non-small cell lung cancer (NSCLC).
    Lung Cancer. 2021;160:92-98.
    PubMed     Abstract available

  35. MOORE DA, Benafif S, Poskitt B, Argue S, et al
    Optimising fusion detection through sequential DNA and RNA molecular profiling of non-small cell lung cancer.
    Lung Cancer. 2021;161:55-59.
    PubMed     Abstract available

  36. KULASINGHE A, O'Leary C, Monkman J, Bharti V, et al
    The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC).
    Lung Cancer. 2021;160:73-77.
    PubMed     Abstract available

  37. VOGGEL S, Abele M, Seitz C, Agaimy A, et al
    Primary lung carcinoma in children and adolescents - Clinical characteristics and outcome of 12 cases from the German registry for rare paediatric tumours (STEP).
    Lung Cancer. 2021;160:66-72.
    PubMed     Abstract available

  38. CHEUNG CC, Smith AC, Albadine R, Bigras G, et al
    Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.
    Lung Cancer. 2021;160:127-135.
    PubMed     Abstract available

  39. VAUCHIER C, Pluvy J, Theou-Anton N, Soussi G, et al
    Poor performance status patient with long-lasting major response to pembrolizumab in advanced non-small-cell lung cancer with coexisting POLE mutation and deficient mismatch repair pathway.
    Lung Cancer. 2021;160:28-31.
    PubMed     Abstract available

  40. STEENDAM CMJ, Peric R, van Walree NC, Youssef M, et al
    Randomized phase III study of docetaxel versus docetaxel plus intercalated erlotinib in patients with relapsed non-squamous non-small cell lung carcinoma.
    Lung Cancer. 2021;160:44-49.
    PubMed     Abstract available

  41. VERMA V
    Stereotactic radiotherapy for early-stage (T1-2N0) small cell lung cancer: Where are we now and where are we going?
    Lung Cancer. 2021 Aug 3. pii: S0169-5002(21)00485.

  42. BUMA AIG, Muller M, de Vries R, Sterk PJ, et al
    eNose analysis for early immunotherapy response monitoring in non-small cell lung cancer.
    Lung Cancer. 2021;160:36-43.
    PubMed     Abstract available

  43. ZHANG SS, Nagasaka M, Zhu VW, Ou SI, et al
    Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
    Lung Cancer. 2021;158:126-136.
    PubMed     Abstract available

  44. NAKASONE S, Suzuki A, Okazaki H, Onodera K, et al
    Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients.
    Lung Cancer. 2021;158:115-125.
    PubMed     Abstract available

  45. TOMASIK B, Bienkowski M, Braun M, Popat S, et al
    Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score >/=2 - Systematic review and meta-analysis.
    Lung Cancer. 2021;158:97-106.
    PubMed     Abstract available

  46. YOSHIDA C, Kadota K, Ikeda T, Ibuki E, et al
    Tumor-associated macrophage infiltration is associated with a higher rate of tumor spread through air spaces in resected lung adenocarcinomas.
    Lung Cancer. 2021;158:91-96.
    PubMed     Abstract available

  47. HE Z, Zhu X, Zeng Q, Yu Z, et al
    A novel 5'ALK fusion identified by next generation sequencing and validated by IHC in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;158:164-165.

  48. FEKKAR A, Emprou C, Lefebvre C, Ferretti G, et al
    Thoracic NUT carcinoma: Common pathological features despite diversity of clinical presentations.
    Lung Cancer. 2021;158:55-59.
    PubMed     Abstract available

  49. LU A, Shi Y, Liu Y, Lin J, et al
    Integrative analyses identified ion channel genes GJB2 and SCNN1B as prognostic biomarkers and therapeutic targets for lung adenocarcinoma.
    Lung Cancer. 2021;158:29-39.
    PubMed     Abstract available

  50. LIU SV
    NRG1 fusions: Biology to therapy.
    Lung Cancer. 2021;158:25-28.
    PubMed     Abstract available

  51. KUIJVENHOVEN JC, Livi V, Szlubowski A, Ninaber M, et al
    Endobronchial ultrasound for T4 staging in patients with resectable NSCLC.
    Lung Cancer. 2021;158:18-24.
    PubMed     Abstract available

  52. CYTRYN S, Ferreira V, Boland P, Chachoua A, et al
    Durvalumab consolidation therapy in a patient with stage IIIB unresectable NSCLC harboring a MET exon 14 splice site alteration.
    Lung Cancer. 2021;158:15-17.
    PubMed     Abstract available

  53. INGLEY KM, Hughes D, Hubank M, Lindsay D, et al
    Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT).
    Lung Cancer. 2021;158:151-155.
    PubMed     Abstract available

  54. CHEN X, Xu BO, Fu F, Cai K, et al
    A Novel Nonreciprocal/Reciprocal ALK Translocation Cause ALK+ in NSCLC.
    Lung Cancer. 2021;158:162-163.

    July 2021
  55. YOH K, Matsumoto S, Furuya N, Nishino K, et al
    Comprehensive assessment of PD-L1 expression, tumor mutational burden and oncogenic driver alterations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2021;159:128-134.
    PubMed     Abstract available

  56. KOOMEN BM, Voorham QJM, Epskamp-Kuijpers CCHJ, van Dooijeweert C, et al
    Considerable interlaboratory variation in PD-L1 positivity in a nationwide cohort of non-small cell lung cancer patients.
    Lung Cancer. 2021;159:117-126.
    PubMed     Abstract available

  57. KOZONO DE, Stinchcombe TE, Salama JK, Bogart J, et al
    Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer.
    Lung Cancer. 2021;159:56-65.
    PubMed     Abstract available

  58. ZHAO M, Wu J, Deng J, Wang T, et al
    Proposal for Rib invasion as an independent T descriptor for non-small cell lung cancer: A propensity-score matching analysis.
    Lung Cancer. 2021;159:27-33.
    PubMed     Abstract available

  59. DIAZ M, Garcia M, Vidal C, Santiago A, et al
    Health and economic impact at a population level of both primary and secondary preventive lung cancer interventions: A model-based cost-effectiveness analysis.
    Lung Cancer. 2021;159:153-161.
    PubMed     Abstract available

  60. SAFAVI AH, Mak DY, Boldt RG, Chen H, et al
    Stereotactic ablative radiotherapy in T1-2N0M0 small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021 Jul 21. pii: S0169-5002(21)00472.
    PubMed     Abstract available

  61. WANG X, Guo Y, Liu L, Wei J, et al
    YAP1 protein expression has variant prognostic significance in small cell lung cancer (SCLC) stratified by histological subtypes.
    Lung Cancer. 2021 Jul 21. pii: S0169-5002(21)00456.
    PubMed     Abstract available

  62. RAD HS, Rad HS, Shiravand Y, Radfar P, et al
    The Pandora's box of novel technologies that may revolutionize lung cancer.
    Lung Cancer. 2021;159:34-41.
    PubMed     Abstract available

  63. VAN BREESCHOTEN J, Ismail R, Smit H, Schuurbiers O, et al
    An invisible group of COVID-19 victims; impact on Dutch lung cancer care.
    Lung Cancer. 2021 Jul 19. pii: S0169-5002(21)00476.

  64. CHO BC, Yoh K, Perets R, Nagrial A, et al
    Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer.
    Lung Cancer. 2021;159:162-170.
    PubMed     Abstract available

  65. SHEN Y, Zhang Y, Guo Y, Li W, et al
    Prognosis of lung cancer associated with cystic airspaces: A propensity score matching analysis.
    Lung Cancer. 2021;159:111-116.
    PubMed     Abstract available

  66. KOCHER F, Tymoszuk P, Amann A, Sprung S, et al
    Deregulated glutamate to pro-collagen conversion is associated with adverse outcome in lung cancer and may be targeted by renin-angiotensin-aldosterone system (RAS) inhibition.
    Lung Cancer. 2021;159:84-95.
    PubMed     Abstract available

  67. USUZAKI T, Takahashi K, Umemiya K, Ishikuro M, et al
    Augmentation method for convolutional neural network that improves prediction performance in the task of classifying primary lung cancer and lung metastasis using CT images.
    Lung Cancer. 2021 Jul 16. pii: S0169-5002(21)00468.

  68. LINDSAY CR, Garassino MC, Nadal E, Ohrling K, et al
    On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
    Lung Cancer. 2021 Jul 16. pii: S0169-5002(21)00474.
    PubMed     Abstract available

  69. BHALLA S, Bakouny Z, Schmidt AL, Labaki C, et al
    Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.
    Lung Cancer. 2021;160:78-83.
    PubMed     Abstract available

  70. FUNG AS, Graham DM, Chen EX, Stockley TL, et al
    A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer.
    Lung Cancer. 2021;157:21-29.
    PubMed     Abstract available

  71. POPAT S, Brustugun OT, Cadranel J, Felip E, et al
    Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer.
    Lung Cancer. 2021;157:9-16.
    PubMed     Abstract available

  72. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174-184].
    Lung Cancer. 2021;157:167.

  73. CLERMIDY H, Maury JM, Collaud S, Drevet G, et al
    Lymph Node Dissection in Thymoma: Is it worth it?
    Lung Cancer. 2021;157:156-162.
    PubMed     Abstract available

  74. XIE XJ, Liu SY, Chen JY, Zhao Y, et al
    Development of unenhanced CT-based imaging signature for BAP1 mutation status prediction in malignant pleural mesothelioma: Consideration of 2D and 3D segmentation.
    Lung Cancer. 2021;157:30-39.
    PubMed     Abstract available

  75. TALCOTT WJ, Miccio JA, Park HS, White AA, et al
    Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ.
    Lung Cancer. 2021;157:17-20.
    PubMed     Abstract available

  76. ZHU VW, Zhao JJ, Gao Y, Syn NL, et al
    Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
    Lung Cancer. 2021;157:147-155.
    PubMed     Abstract available

  77. LESIRE B, Durieux V, Grigoriu B, Girard N, et al
    Management of thymoma associated autoimmune pure red cell aplasia: Case report and systematic review of the literature.
    Lung Cancer. 2021;157:131-146.
    PubMed     Abstract available

  78. SUGIMOTO A, Umemura S, Miyoshi T, Nakai T, et al
    High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.
    Lung Cancer. 2021;157:1-8.
    PubMed     Abstract available

  79. YANG Y, Ran J, Wang Y, Zhou Z, et al
    Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases.
    Lung Cancer. 2021;157:116-123.
    PubMed     Abstract available

  80. PASSIGLIA F, Leone G, Olmetto E, Delcuratolo MD, et al
    Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era.
    Lung Cancer. 2021;157:85-91.
    PubMed     Abstract available

  81. BASSE C, Daniel C, Livartowski A, Beaucaire-Danel S, et al
    Impact of COVID-19 on the management of patients with thoracic cancers in a tertiary referral center.
    Lung Cancer. 2021;157:79-84.
    PubMed     Abstract available

  82. CHINTALA NK, Restle D, Quach H, Saini J, et al
    CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials.
    Lung Cancer. 2021;157:48-59.
    PubMed     Abstract available

  83. CERESOLI GL, Ghirardelli P, Franceschini D, Scorsetti M, et al
    A reply to "managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy".
    Lung Cancer. 2021;157:165-166.

  84. BARSKY AR, Yegya-Raman N, Katz SI, Simone CB 2nd, et al
    Managing oligoprogressive malignant pleural mesothelioma with stereotactic body radiation therapy.
    Lung Cancer. 2021;157:163-164.

    June 2021
  85. SU PL, Tsai JS, Yang SC, Wu YL, et al
    Survival benefit of osimertinib combination therapy in patients with T790M-positive non-small-cell lung cancer refractory to osimertinib treatment.
    Lung Cancer. 2021;158:137-145.
    PubMed     Abstract available

  86. WANG Z, Zhao J, Ma Z, Cui J, et al
    Corrigendum to "A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients" [Lung Cancer 147 (2020) 259-268].
    Lung Cancer. 2021 Jun 11. pii: S0169-5002(21)00426.

  87. BORG M, Wen SWC, Nederby L, Hansen TF, et al
    Performance of the EarlyCDT(R) Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort.
    Lung Cancer. 2021;158:85-90.
    PubMed     Abstract available

  88. QI M, Bian D, Zhang J, Zhu X, et al
    The modification of T description according to visceral pleural invasion and tumor size from 3.1cm to 4.0cm in non-small cell lung cancer: A retrospective analysis based on the SEER database.
    Lung Cancer. 2021;158:47-54.
    PubMed     Abstract available

  89. MELOSKY B, Wheatley-Price P, Juergens RA, Sacher A, et al
    The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Lung Cancer. 2021 Jun 5. pii: S0169-5002(21)00429.
    PubMed     Abstract available

  90. JOSHI K, Muhith A, Obeid M, Milner-Watts C, et al
    Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond.
    Lung Cancer. 2021;156:147-150.
    PubMed     Abstract available

  91. GACHECHILADZE M, Uberall I, Skanderova D, Matchavariani J, et al
    LC3A positive "stone like structures" are differentially associated with survival outcomes and CD68 macrophage infiltration in patients with lung adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2021;156:129-135.
    PubMed     Abstract available

  92. LAROSE F, Quigley N, Lacasse Y, Martel S, et al
    Malignant pleural mesothelioma: Comparison of surgery-based trimodality therapy to medical therapy at two tertiary academic institutions.
    Lung Cancer. 2021;156:151-156.
    PubMed     Abstract available

  93. PRIETO M, Chassagnon G, Lupo A, Charpentier MC, et al
    Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features.
    Lung Cancer. 2021;156:117-121.
    PubMed     Abstract available

  94. SOLDATH P, Binderup T, Kjaer A, Federspiel B, et al
    Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients.
    Lung Cancer. 2021;156:109-116.
    PubMed     Abstract available

  95. LAU SCM, Poletes C, Le LW, Mackay KM, et al
    Durability of CNS disease control in NSCLC patients with brain metastases treated with immune checkpoint inhibitors plus cranial radiotherapy.
    Lung Cancer. 2021;156:76-81.
    PubMed     Abstract available

  96. NAKASUKA T, Ohashi K, Watanabe H, Kubo T, et al
    A case of dramatic reduction in cancer-associated thrombus following initiation of pembrolizumab in patient with a poor performance status and PD-L1(+) lung adenocarcinoma harboring CCDC6-RET fusion gene and NF1/TP53 mutations.
    Lung Cancer. 2021;156:1-4.
    PubMed     Abstract available

    May 2021
  97. KIM HW, Kim JS, Lee SH
    Incidence of tuberculosis in advanced lung cancer patients treated with immune checkpoint inhibitors - A nationwide population-based cohort study.
    Lung Cancer. 2021;158:107-114.
    PubMed     Abstract available

  98. GUO T, Zhu L, Li W, Lin R, et al
    Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation.
    Lung Cancer. 2021;161:94-97.
    PubMed     Abstract available

  99. SATO T, Shimada Y, Mimae T, Tsutani Y, et al
    The impact of pathological lymph node metastasis with lymphatic invasion on the survival of patients with clinically node-negative non-small cell lung cancer: A multicenter study.
    Lung Cancer. 2021;158:9-14.
    PubMed     Abstract available

  100. HE LN, Fu S, Zhang X, Hu Q, et al
    Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.
    Lung Cancer. 2021;158:1-8.
    PubMed     Abstract available

  101. LAVOLE A, Mazieres J, Schneider S, Brosseau S, et al
    Assessment of nivolumab in HIV-Infected patients with advanced non-small cell lung cancer after prior chemotherapy. The IFCT-1602 CHIVA2 phase 2 clinical trial.
    Lung Cancer. 2021;158:146-150.
    PubMed     Abstract available

  102. DI STASIO GD, Travascio L, Colandrea M, Spaggiari L, et al
    Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution.
    Lung Cancer. 2021;158:40-46.
    PubMed     Abstract available

  103. GOKER E, Altwairgi A, Al-Omair A, Tfayli A, et al
    Multi-disciplinary approach for the management of non-metastatic non-small cell lung cancer in the Middle East and Africa: Expert panel recommendations.
    Lung Cancer. 2021;158:60-73.
    PubMed     Abstract available

  104. LIU R, Ota K, Iwama E, Yoneshima Y, et al
    Quantification of HER family dimers by proximity ligation assay and its clinical evaluation in non-small cell lung cancer patients treated with osimertinib.
    Lung Cancer. 2021 May 25. pii: S0169-5002(21)00403.
    PubMed     Abstract available

  105. SPIRA AI, Tu H, Aggarwal S, Hsu H, et al
    A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
    Lung Cancer. 2021;159:1-9.
    PubMed     Abstract available

  106. OSTI MF, Agolli L, Valeriani M, Reverberi C, et al
    Erratum to "30 Gy single dose stereotactic body radiation therapy (SBRT): Report on outcome in a large series of patients with lung oligometastatic disease" [Lung Cancer 122 (2018) 165-170].
    Lung Cancer. 2021 May 21. pii: S0169-5002(21)00187.

  107. DUVERGE L, Bondiau PY, Claude L, Supiot S, et al
    Discontinuous stereotactic body radiotherapy schedule increases overall survival in early-stage non-small cell lung cancer.
    Lung Cancer. 2021 May 15. pii: S0169-5002(21)00195.
    PubMed     Abstract available

  108. PROVENCIO M, Mazarico Gallego JM, Calles A, Antonanzas M, et al
    Lung cancer patients with COVID-19 in Spain: GRAVID study.
    Lung Cancer. 2021 May 14. pii: S0169-5002(21)00193.
    PubMed     Abstract available

  109. WISLEZ M, Domblides C, Greillier L, Mazieres J, et al
    Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA).
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00192.
    PubMed     Abstract available

  110. PILLERON S, Maringe C, Charvat H, Atkinson J, et al
    Age disparities in lung cancer survival in New Zealand: The role of patient and clinical factors.
    Lung Cancer. 2021 May 13. pii: S0169-5002(21)00194.
    PubMed     Abstract available

  111. ROGASCH JMM, Frost N, Bluemel S, Michaels L, et al
    FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow.
    Lung Cancer. 2021 May 7. pii: S0169-5002(21)00171.
    PubMed     Abstract available

  112. LEI H, Yang Y, Zhou W, Zhang M, et al
    Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis.
    Lung Cancer. 2021 May 5. pii: S0169-5002(21)00170.
    PubMed     Abstract available

  113. WANG LL, Yu H, Wang HY, Liu T, et al
    Comment on: Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Lung Cancer. 2021 May 3. pii: S0169-5002(21)00168.

    The future in the instant: The lung adenocarcinoma classification as a predictor of future adverse events.
    Lung Cancer. 2021;155:191-192.

  115. HALMOS B, Burke T, Kalyvas C, Vandormael K, et al
    Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/-bevacizumab for the first-line treatment of non-squamous NSCLC: A matching-adjusted indirect comparison.
    Lung Cancer. 2021;155:175-182.
    PubMed     Abstract available

  116. SUMI T, Nakata H, Chiba H
    Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment.
    Lung Cancer. 2021;155:196-198.

  117. LUO Y, Wei J, Zhang J, Zeng L, et al
    Two different patients with pulmonary pleomorphic carcinoma response to PD-1 inhibitor plus anlotinib.
    Lung Cancer. 2021;155:170-174.
    PubMed     Abstract available

  118. NOORDHOF AL, Damhuis RAM, Hendriks LEL, de Langen AJ, et al
    Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
    Lung Cancer. 2021;155:163-169.
    PubMed     Abstract available

  119. VAN DE STADT EA, Yaqub M, Lammertsma AA, Poot AJ, et al
    Identifying advanced stage NSCLC patients who benefit from afatinib therapy using (18)F-afatinib PET/CT imaging.
    Lung Cancer. 2021;155:156-162.
    PubMed     Abstract available

  120. LV W, Wang Y, Zhou C, Yuan M, et al
    Development and validation of a clinically applicable deep learning strategy (HONORS) for pulmonary nodule classification at CT: A retrospective multicentre study.
    Lung Cancer. 2021;155:78-86.
    PubMed     Abstract available

  121. ZHAO D, Hou F, Li M, Qi Y, et al
    A novel KLHL6/KLHL24 intergenic region-NTRK3 fusion in a patient with lung squamous cell carcinoma.
    Lung Cancer. 2021;155:193-195.

  122. MORENO-RUIZ P, Corvigno S, Te Grootenhuis NC, La Fleur L, et al
    Stromal FAP is an independent poor prognosis marker in non-small cell lung adenocarcinoma and associated with p53 mutation.
    Lung Cancer. 2021;155:10-19.
    PubMed     Abstract available

  123. FOREST F, Casteillo F, Da Cruz V, Yvorel V, et al
    Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
    Lung Cancer. 2021;155:1-9.
    PubMed     Abstract available

  124. ARRIETA O, Salas AA, Cardona AF, Diaz-Garcia D, et al
    Risk of development of brain metastases according to the IASLC/ATS/ERS lung adenocarcinoma classification in locally advanced and metastatic disease.
    Lung Cancer. 2021;155:183-190.
    PubMed     Abstract available

    April 2021
  125. DEBIEUVRE D, Juergens RA, Asselain B, Audigier-Valette C, et al
    Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
    Lung Cancer. 2021 Apr 30. pii: S0169-5002(21)00165.
    PubMed     Abstract available

  126. CHEN N, Li Q, Wang S, Xiong M, et al
    Hypo-fractionated radiotherapy with concurrent chemotherapy for locoregional recurrence of non-small cell lung cancer after complete resection: A prospective, single-arm, phase II study (GASTO-1017).
    Lung Cancer. 2021;156:82-90.
    PubMed     Abstract available

  127. NEWMAN NB, Osmundson EC
    Practical demonstration of time bias with administration of adjuvant therapy in lung cancer.
    Lung Cancer. 2021 Apr 26. pii: S0169-5002(21)00161.
    PubMed     Abstract available

  128. FROESCH P, Mark M, Rothschild SI, Li Q, et al
    Binimetinib, pemetrexed and cisplatin, followed by maintenance of binimetinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) and KRAS mutations. The phase 1B SAKK 19/16 trial.
    Lung Cancer. 2021;156:91-99.
    PubMed     Abstract available

  129. PALL G, Gautschi O
    Advances in the treatment of RET-fusion-positive lung cancer.
    Lung Cancer. 2021 Apr 24. pii: S0169-5002(21)00159.
    PubMed     Abstract available

  130. KUZDZAL J, Trybalski L, Hauer L, Cmiel A, et al
    Influence of bilateral mediastinal lymph node dissection on survival in non-small cell lung cancer patients - Randomized study.
    Lung Cancer. 2021 Apr 22. pii: S0169-5002(21)00160.
    PubMed     Abstract available

  131. TAMMEMAGI MC, Darling GE, Schmidt H, Llovet D, et al
    Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience.
    Lung Cancer. 2021;156:31-40.
    PubMed     Abstract available

  132. ZHANG CC, Hou RP, Xia WY, Zeng WQ, et al
    Prognostic index for estimating the survival benefit of postoperative radiotherapy in pathologic N2 non-small cell lung cancer: A real-world validation study.
    Lung Cancer. 2021;156:100-108.
    PubMed     Abstract available

  133. HORIUCHI K, Sato T, Kuno T, Takagi H, et al
    Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2021;156:59-67.
    PubMed     Abstract available

  134. BOGART JA, Wang X, Masters GA, Gao J, et al
    Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538.
    Lung Cancer. 2021;156:68-71.
    PubMed     Abstract available

  135. HSU CL, Tsai TH, Huang CK, Yang CY, et al
    Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer.
    Lung Cancer. 2021;156:50-58.
    PubMed     Abstract available

  136. VON DER THUSEN JH, Dumoulin DW, Maat APWM, Wolf J, et al
    ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype.
    Lung Cancer. 2021;156:72-75.
    PubMed     Abstract available

  137. MILLER HA, Yin X, Smith SA, Hu X, et al
    Evaluation of disease staging and chemotherapeutic response in non-small cell lung cancer from patient tumor-derived metabolomic data.
    Lung Cancer. 2021;156:20-30.
    PubMed     Abstract available

  138. ITO S, Asahina H, Honjo O, Tanaka H, et al
    Prognostic factors in patients with advanced non-small cell lung cancer after long-term Anti-PD-1 therapy (HOT1902).
    Lung Cancer. 2021;156:12-19.
    PubMed     Abstract available

  139. WATERHOUSE D, Lam J, Betts KA, Yin L, et al
    Real-world outcomes of immunotherapy-based regimens in first-line advanced non-small cell lung cancer.
    Lung Cancer. 2021;156:41-49.
    PubMed     Abstract available

  140. SCHREUDER A, Mets OM, Schaefer-Prokop CM, Jacobs C, et al
    Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial.
    Lung Cancer. 2021;156:5-11.
    PubMed     Abstract available

  141. VISSER MPJ, van Grimbergen I, Holters J, Barendregt WB, et al
    Performance insights of endobronchial ultrasonography (EBUS) and mediastinoscopy for mediastinal lymph node staging in lung cancer.
    Lung Cancer. 2021 Apr 7. pii: S0169-5002(21)00132.
    PubMed     Abstract available

  142. YANG L, Zhao W, Zhu H, Li X, et al
    PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
    Lung Cancer. 2021;154:219-220.

  143. COSTA FA, Amano MT, Asprino PF, Pavlick DC, et al
    Revealing the BRD4-NOTCH3 fusion: A novel hill in the cancer landscape.
    Lung Cancer. 2021;154:146-150.
    PubMed     Abstract available

  144. VOLCKMAR AL, Christopoulos P, Kirchner M, Allgauer M, et al
    Targeting rare and non-canonical driver variants in NSCLC - An uncharted clinical field.
    Lung Cancer. 2021;154:131-141.
    PubMed     Abstract available

  145. XIONG A, Li C, Xu J, Yang X, et al
    Solid subtype predicts early bone metastases in sensitive EGFR-mutated lung adenocarcinoma patients after surgery.
    Lung Cancer. 2021;154:124-130.
    PubMed     Abstract available

  146. SHANG X, Li Z, Sun J, Zhao C, et al
    Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab.
    Lung Cancer. 2021;154:105-112.
    PubMed     Abstract available

  147. WANG YL, Wu ZZ, Zhang HR, Chen DS, et al
    Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
    Lung Cancer. 2021;154:216-218.

  148. ZHANG C, Wang H
    Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors.
    Lung Cancer. 2021;154:221-223.

  149. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.
    Lung Cancer. 2021;154:92-98.
    PubMed     Abstract available

  150. ZHANG C, Wang H
    The source of the tumor tissue should be taken into consideration when distinguishing tumor mutational burden scores.
    Lung Cancer. 2021;154:214-215.

  151. WEISSFERDT A, Pataer A, Swisher SG, Heymach JV, et al
    Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
    Lung Cancer. 2021;154:76-83.
    PubMed     Abstract available

  152. LI Z, Li F, Pan C, He Z, et al
    Tumor cell proliferation (Ki-67) expression and its prognostic significance in histological subtypes of lung adenocarcinoma.
    Lung Cancer. 2021;154:69-75.
    PubMed     Abstract available

  153. COLLAUD S, Alnajdawi Y, Stork T, Plones T, et al
    Preoperative chest computed tomography evaluation for predicting intraoperative lung resection strongly depends on interpreters experience.
    Lung Cancer. 2021;154:23-28.
    PubMed     Abstract available

  154. KATZ SI, Roshkovan L, Berger I, Friedberg JS, et al
    Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Lung Cancer. 2021;154:5-12.
    PubMed     Abstract available

  155. PATHIPATI MP, Yohannan TK, Tian L, Hornbacker K, et al
    Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study.
    Lung Cancer. 2021;154:186-194.
    PubMed     Abstract available

    March 2021
  156. BISSONNETTE JP, Sun A, Grills IS, Almahariq MF, et al
    Non-small cell lung cancer stage migration as a function of wait times from diagnostic imaging: A pooled analysis from five international centres.
    Lung Cancer. 2021;155:136-143.
    PubMed     Abstract available

  157. FURUKAWA R, Inoue H, Yoneshima Y, Tsutsumi H, et al
    Cytotoxic chemotherapeutic agents and the EGFR-TKI osimertinib induce calreticulin exposure in non-small cell lung cancer.
    Lung Cancer. 2021;155:144-150.
    PubMed     Abstract available

  158. EPAILLARD N, Benitez JC, Gorria T, Fabre E, et al
    Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study.
    Lung Cancer. 2021;155:114-119.
    PubMed     Abstract available

  159. TASAKA Y, Honda T, Nishiyama N, Tsutsui T, et al
    Non-inferior clinical outcomes of immune checkpoint inhibitors in non-small cell lung cancer patients with interstitial lung disease.
    Lung Cancer. 2021;155:120-126.
    PubMed     Abstract available

  160. EVERS J, de Jaeger K, Hendriks LEL, van der Sangen M, et al
    Trends and variations in treatment of stage I-III non-small cell lung cancer from 2008 to 2018: A nationwide population-based study from the Netherlands.
    Lung Cancer. 2021;155:103-113.
    PubMed     Abstract available

  161. TAO J, Jatoi A, Crawford J, Lam WWT, et al
    Role of dietary carbohydrates on risk of lung cancer.
    Lung Cancer. 2021;155:87-93.
    PubMed     Abstract available

  162. YUN JK, Lee GD, Choi S, Kim HR, et al
    The addition of radiotherapy to adjuvant chemotherapy has a combinatorial effect in pN2 non-small cell lung cancer only with extranodal invasion or multiple N2 metastasis.
    Lung Cancer. 2021;155:94-102.
    PubMed     Abstract available

  163. PARK K, Chang GC, Curigliano G, Lim WT, et al
    Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation.
    Lung Cancer. 2021;155:127-135.
    PubMed     Abstract available

  164. AREDO JV, Purington N, Su L, Luo SJ, et al
    Metabolomic profiling for second primary lung cancer: A pilot case-control study.
    Lung Cancer. 2021;155:61-67.
    PubMed     Abstract available

  165. DAMHUS CS, Quentin JG, Malmqvist J, Siersma V, et al
    Psychosocial consequences of a three-month follow-up after receiving an abnormal lung cancer CT-screening result: A longitudinal survey.
    Lung Cancer. 2021;155:46-52.
    PubMed     Abstract available

  166. YOH K, Seto T, Satouchi M, Nishio M, et al
    Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.
    Lung Cancer. 2021;155:40-45.
    PubMed     Abstract available

  167. LIU J, Itchins M, Nagrial A, Cooper WA, et al
    Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2021;155:28-33.
    PubMed     Abstract available

  168. WANG W, Xu C, Chen H, Jia J, et al
    Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
    Lung Cancer. 2021;155:20-27.
    PubMed     Abstract available

  169. GARCIA CAMPELO MR, Lin HM, Zhu Y, Perol M, et al
    Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+non-small cell lung cancer (ALTA-1L).
    Lung Cancer. 2021;155:68-77.
    PubMed     Abstract available

  170. HASSAN A, Latif MT, Soo CI, Faisal AH, et al
    Corrigendum to "Short communication: Diagnosis of lung cancer increases during the annual southeast Asian haze periods" [Lung Cancer 113 (2017) 1-3].
    Lung Cancer. 2021 Mar 4. pii: S0169-5002(21)00084.

  171. MORENO V, Garrido P, Papadopoulos KP, De Miguel Luken MJ, et al
    Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort.
    Lung Cancer. 2021;155:151-155.
    PubMed     Abstract available

  172. ATTILI I, Tarantino P, Passaro A, Stati V, et al
    Strategies to overcome resistance to immune checkpoint blockade in lung cancer.
    Lung Cancer. 2021;154:151-160.
    PubMed     Abstract available

  173. MORAES FY, Mansouri A, Dasgupta A, Ramotar M, et al
    Impact of EGFR mutation on outcomes following SRS for brain metastases in non-small cell lung cancer.
    Lung Cancer. 2021;155:34-39.
    PubMed     Abstract available

    A reply to "Cardiac dysfunction due to Osimertinib".
    Lung Cancer. 2021;153:195.

  175. BOMMART S, Pujol JL, Coffy A, Daures JP, et al
    Authors reply to letter to the editor by Dr Degens et al.
    Lung Cancer. 2021;153:185.

  176. ANAND K
    Cardiac dysfunction due to Osimertinib.
    Lung Cancer. 2021;153:193-194.

  177. BABA K, Yoshida T, Shiotsuka M, Kobayashi O, et al
    Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient.
    Lung Cancer. 2021;153:182-183.

  178. ARAUJO-FILHO JAB, Chang J, Mayoral M, Plodkowski AJ, et al
    Are there imaging characteristics that can distinguish separate primary lung carcinomas from intrapulmonary metastases using next-generation sequencing as a gold standard?
    Lung Cancer. 2021;153:158-164.
    PubMed     Abstract available

  179. FUCHS V, Roisman L, Kian W, Daniel L, et al
    The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.
    Lung Cancer. 2021;153:126-133.
    PubMed     Abstract available

  180. LI R, Jiang L, Zhou X, Lu Y, et al
    Pseudo-small cell transformation in EGFR-mutant adenocarcinoma.
    Lung Cancer. 2021;153:120-125.
    PubMed     Abstract available

  181. MASRORI P, Vaesen Bentein H, Raskin J, Montagna M, et al
    Caspr2 autoantibody-associated Morvan syndrome predating thymoma relapse by 30 months.
    Lung Cancer. 2021;153:117-119.
    PubMed     Abstract available

  182. ZHAI X, Wu Q, Zeng Z, Suo J, et al
    OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:171-173.

  183. WANG B, Chen R, Wang C, Chen H, et al
    PLB1-ALK: A novel head-to-head fusion gene identified by next-generation sequencing in a lung adenocarcinoma patient.
    Lung Cancer. 2021;153:176-178.

  184. REN P, Luo N, Qi Y, Wu Y, et al
    A novel TNIP2-RET fusion identified in a patient with mucinous adenocarcinoma of the lung.
    Lung Cancer. 2021;153:179-181.

  185. DEVEAUX AE, Allen TA, Al Abo M, Qin X, et al
    RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry.
    Lung Cancer. 2021;153:90-98.
    PubMed     Abstract available

  186. LIU Y, Gao GF, Minna JD, Williams NS, et al
    Loss of wild type KRAS in KRAS(MUT) lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors.
    Lung Cancer. 2021;153:73-80.
    PubMed     Abstract available

  187. ZHOU F, Huang Y, Cai W, Li J, et al
    The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients.
    Lung Cancer. 2021;153:66-72.
    PubMed     Abstract available

  188. AMEMIYA R, Miyoshi T, Aokage K, Suzuki J, et al
    Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
    Lung Cancer. 2021;153:56-65.
    PubMed     Abstract available

  189. CHIA PL, Parakh S, Russell P, Gan HK, et al
    Expression of EGFR and conformational forms of EGFR in malignant pleural mesothelioma and its impact on survival.
    Lung Cancer. 2021;153:35-41.
    PubMed     Abstract available

  190. SUZUKI J, Aokage K, Neri S, Sakai T, et al
    Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma.
    Lung Cancer. 2021;153:1-10.
    PubMed     Abstract available

  191. KUNIMASA K, Oka T, Hara S, Yamada N, et al
    Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction.
    Lung Cancer. 2021;153:186-192.
    PubMed     Abstract available

    February 2021
  192. LIU L, Bai H, Seery S, Li S, et al
    Efficacy and safety of treatment modalities across EGFR selected/unselected populations with non-small cell lung cancer and brain metastases: A systematic review and Bayesian network meta-analysis.
    Lung Cancer. 2021;158:74-84.
    PubMed     Abstract available

  193. LIU G, Brenner H, Chen C, Christiani D, et al
    A reply to "Lung cancer outcomes: Are BMI and race clinically relevant?"
    Lung Cancer. 2021 Feb 26. pii: S0169-5002(21)00079.

  194. WONG SK, Alex D, Bosdet I, Hughesman C, et al
    MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
    Lung Cancer. 2021;154:142-145.
    PubMed     Abstract available

  195. CHENG Y, Mok TS, Zhou X, Lu S, et al
    Safety and efficacy of first-line dacomitinib in Asian patients with EGFR mutation-positive non-small cell lung cancer: Results from a randomized, open-label, phase 3 trial (ARCHER 1050).
    Lung Cancer. 2021;154:176-185.
    PubMed     Abstract available

  196. FOURDRAIN A, Epailly J, Blanchard C, Georges O, et al
    Lymphatic drainage of lung cancer follows an intersegmental pathway within the visceral pleura.
    Lung Cancer. 2021;154:118-123.
    PubMed     Abstract available

  197. KOK PS, Lee K, Lord S, Yang JC, et al
    Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.
    Lung Cancer. 2021;154:113-117.
    PubMed     Abstract available

  198. KERR KM, Bibeau F, Thunnissen E, Botling J, et al
    The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.
    Lung Cancer. 2021;154:161-175.
    PubMed     Abstract available

  199. MAO K, Liu F, Liu X, Khuri FR, et al
    Corrigendum to "Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression" [Lung Cancer 88/2 (2015) 131-138].
    Lung Cancer. 2021 Feb 19. pii: S0169-5002(21)00073.

  200. GARON EB, Aerts J, Kim JS, Muehlenbein CE, et al
    Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189.
    Lung Cancer. 2021;155:53-60.
    PubMed     Abstract available

  201. OHARA S, Suda K, Fujino T, Hamada A, et al
    Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancer.
    Lung Cancer. 2021;154:84-91.
    PubMed     Abstract available

  202. LIU F, Liu Y, Liu X, Mao K, et al
    Corrigendum to "Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer" [Lung Cancer 123 (2018) 36-43].
    Lung Cancer. 2021 Feb 18. pii: S0169-5002(21)00072.

  203. CHENG H, Zou Y, Shah CD, Fan N, et al
    First-in-human study of inhaled Azacitidine in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2021;154:99-104.
    PubMed     Abstract available

  204. AHMED Z, Kennedy K, Subramanian J
    The role for chemotherapy in 80 years and older patients with metastatic non-small cell lung cancer: A National cancer database analysis.
    Lung Cancer. 2021;154:62-68.
    PubMed     Abstract available

  205. CHEN X, Muhammad KG, Madeeha C, Fu W, et al
    Calculated indices of volatile organic compounds (VOCs) in exhalation for lung cancer screening and early detection.
    Lung Cancer. 2021 Feb 14. pii: S0169-5002(21)00065.
    PubMed     Abstract available

  206. SEBASTIAN M, Eberhardt WEE, Hoffknecht P, Metzenmacher M, et al
    KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Lung Cancer. 2021;154:51-61.
    PubMed     Abstract available

  207. HENG WS, Pore M, Meijer C, Hiltermann TJN, et al
    A unique small cell lung carcinoma disease progression model shows progressive accumulation of cancer stem cell properties and CD44 as a potential diagnostic marker.
    Lung Cancer. 2021;154:13-22.
    PubMed     Abstract available

  208. SPAGGIARI L, Bertolaccini L, Facciolo F, Gallina FT, et al
    A risk stratification scheme for synchronous oligometastatic non-small cell lung cancer developed by a multicentre analysis.
    Lung Cancer. 2021;154:29-35.
    PubMed     Abstract available

  209. LAMOTE K, Van den Heuvel MM
    Where the nose is going to help the eye: Sniffing lung cancer.
    Lung Cancer. 2021 Feb 10. pii: S0169-5002(21)00063.

  210. PALLARI E, Eriksson M, Billhult A, Billhult T, et al
    Lung cancer research and its citation on clinical practice guidelines.
    Lung Cancer. 2021;154:44-50.
    PubMed     Abstract available

  211. WANG S, Chen H, Zhong J, Qin H, et al
    Corrigendum to "Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung" [Lung Cancer 135 (2019) 116-122].
    Lung Cancer. 2021 Feb 2. pii: S0169-5002(21)00014.

  212. CAI C, Tang Y, Li Y, Chen Y, et al
    Distribution and therapeutic outcomes of intergenic sequence-ALK fusion and coexisting ALK fusions in lung adenocarcinoma patients.
    Lung Cancer. 2021;152:104-108.
    PubMed     Abstract available

  213. LI X, Liu J, Guo M, Cai H, et al
    NSCLC patients with MET non-exon-14 mutations rather than MET exon 14 mutations response to immune checkpoint inhibitors.
    Lung Cancer. 2021;152:202-204.

  214. LAZAREV S, Rosenzweig K, Samstein R, Salgado LR, et al
    Where are we with proton beam therapy for thoracic malignancies? Current status and future perspectives.
    Lung Cancer. 2021;152:157-164.
    PubMed     Abstract available

  215. ZHAO G, Chen L, Xiao M, Yang S, et al
    Rare coexistence of three novel CDCA7-ALK, FSIP2-ALK, ALK-ERLEC1 fusions in a lung adenocarcinoma patient who responded to Crizotinib.
    Lung Cancer. 2021;152:189-192.

  216. MARCUSE F, Hochstenbag M, Hoeijmakers JGJ, Hamid MA, et al
    Subclinical myasthenia gravis in thymomas.
    Lung Cancer. 2021;152:143-148.
    PubMed     Abstract available

  217. HIROSE T, Ikegami M, Endo M, Matsumoto Y, et al
    Extensive functional evaluation of exon 20 insertion mutations of EGFR.
    Lung Cancer. 2021;152:135-142.
    PubMed     Abstract available

  218. LIANG P, Qi L, Guo T, You X, et al
    A possible EGFR TKIs resistance mechanism of lung adenocarcinoma patients with a novel EGFR exon 20-ins mutation: A case report.
    Lung Cancer. 2021;152:193-195.

  219. MA H, Zhang Q, Duan Q, Zhang Q, et al
    Identification of a novel NPM1-ROS1 fusion in a lung adenocarcinoma and sensitive to crizotinib treatment.
    Lung Cancer. 2021;152:196-198.

  220. BLAKE-CERDA M, Lozano-Ruiz F, Maldonado-Magos F, de la Mata-Moya D, et al
    Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: A prospective phase 2 study.
    Lung Cancer. 2021;152:119-126.
    PubMed     Abstract available

  221. GENDARME S, Matton L, Antoine M, Kerrou K, et al
    Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
    Lung Cancer. 2021;152:94-97.
    PubMed     Abstract available

  222. BERGER I, Simpson S, Friedberg JS, Culligan MJ, et al
    CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma.
    Lung Cancer. 2021;152:34-38.
    PubMed     Abstract available

  223. CHAE M, Jeon JH, Chung JH, Lee SY, et al
    Prognostic significance of tumor spread through air spaces in patients with stage IA part-solid lung adenocarcinoma after sublobar resection.
    Lung Cancer. 2021;152:21-26.
    PubMed     Abstract available

  224. KWOK WC, Cheong TF, Chiang KY, Ho JCM, et al
    Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid.
    Lung Cancer. 2021;152:15-20.
    PubMed     Abstract available

  225. GHIRARDELLI P, Franceschini D, D'Aveni A, Dominici L, et al
    Salvage radiotherapy for oligo-progressive malignant pleural mesothelioma.
    Lung Cancer. 2021;152:1-6.
    PubMed     Abstract available

    January 2021
  226. HEUVELMANS MA, van Ooijen PMA, Ather S, Silva CF, et al
    Lung cancer prediction by Deep Learning to identify benign lung nodules.
    Lung Cancer. 2021;154:1-4.
    PubMed     Abstract available

  227. ZOU Y, Wang Y, Jiang Z, Zhou Y, et al
    Breath profile as composite biomarkers for lung cancer diagnosis.
    Lung Cancer. 2021 Jan 30. pii: S0169-5002(21)00038.
    PubMed     Abstract available

  228. GOMES F, Faivre-Finn C, Mistry H, Bezjak A, et al
    Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial.
    Lung Cancer. 2021;153:165-170.
    PubMed     Abstract available

  229. FRIEDES C, Chakrabarti T, Olson S, Prichett L, et al
    Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
    Lung Cancer. 2021;154:36-43.
    PubMed     Abstract available

  230. EICHHORN F, Klotz LV, Kriegsmann M, Bischoff H, et al
    Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
    Lung Cancer. 2021;153:150-157.
    PubMed     Abstract available

  231. CHU X, Zhao J, Zhou J, Zhou F, et al
    Erratum to "Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors" [Lung Cancer 150 (2020
    Lung Cancer. 2021 Jan 15. pii: S0169-5002(21)00015.

  232. HASHEMI S, Fransen MF, Niemeijer A, Ben Taleb N, et al
    Surprising impact of stromal TIL's on immunotherapy efficacy in a real-world lung cancer study.
    Lung Cancer. 2021;153:81-89.
    PubMed     Abstract available

  233. ZHOU J, Yu X, Hou L, Zhao J, et al
    Epidermal growth factor receptor tyrosine kinase inhibitor remodels tumor microenvironment by upregulating LAG-3 in advanced non-small-cell lung cancer.
    Lung Cancer. 2021;153:143-149.
    PubMed     Abstract available

  234. TAKAGI H, Zhao S, Muto S, Yokouchi H, et al
    Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using (125)I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004).
    Lung Cancer. 2021;153:134-142.
    PubMed     Abstract available

  235. CHEN D, Kang P, Tao S, Li Q, et al
    Cost-effectiveness evaluation of robotic-assisted thoracoscopic surgery versus open thoracotomy and video-assisted thoracoscopic surgery for operable non-small cell lung cancer.
    Lung Cancer. 2021;153:99-107.
    PubMed     Abstract available

  236. OHTAKI Y, Shimizu K, Suzuki H, Suzuki K, et al
    Salvage surgery for non-small cell lung cancer after tyrosine kinase inhibitor treatment.
    Lung Cancer. 2021;153:108-116.
    PubMed     Abstract available

  237. IKEDA T, Kadota K, Yoshida C, Ishikawa R, et al
    The epithelial-mesenchymal transition phenotype is associated with the frequency of tumor spread through air spaces (STAS) and a High risk of recurrence after resection of lung carcinoma.
    Lung Cancer. 2021;153:49-55.
    PubMed     Abstract available

  238. PROVENCIO M, Majem M, Guirado M, Massuti B, et al
    Phase II clinical trial with metronomic oral vinorelbine and tri-weekly cisplatin as induction therapy, subsequently concomitant with radiotherapy (RT) in patients with locally advanced, unresectable, non-small cell lung cancer (NSCLC). Analysis of su
    Lung Cancer. 2021;153:25-34.
    PubMed     Abstract available

  239. SANDFELD-PAULSEN B, Aggerholm-Pedersen N, Winther-Larsen A
    Hyponatremia in lung cancer: Incidence and prognostic value in a Danish population-based cohort study.
    Lung Cancer. 2021;153:42-48.
    PubMed     Abstract available

  240. LI Z, Lin Y, Chi X, Xu M, et al
    Appearance of an ALK mutation conferring resistance to crizotinib in non-small cell lung cancer harboring oncogenic ROS1 fusion.
    Lung Cancer. 2021 Jan 8. pii: S0169-5002(21)00007.

  241. BRACKEN-CLARKE D, Kapoor D, Baird AM, Buchanan PJ, et al
    Vaping and lung cancer - A review of current data and recommendations.
    Lung Cancer. 2021;153:11-20.
    PubMed     Abstract available

  242. YANG ZY, Liu ZY, Mu CY, Jiang JH, et al
    Letter: Exploring the accuracy of biopsy in diagnosis of pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:97.

  243. LI X, Zhang D, Li B, Zou B, et al
    Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy.
    Lung Cancer. 2021;151:39-43.
    PubMed     Abstract available

  244. FAIVRE-FINN C, Spigel DR, Senan S, Langer C, et al
    Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).
    Lung Cancer. 2021;151:30-38.
    PubMed     Abstract available

  245. LI M, Tang Q, Chen S, Wang Y, et al
    A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Lung Cancer. 2021;151:98-100.

  246. BUIKHUISEN WA, Steinbusch LC, Kodach LL, Tesselaar MET, et al
    Risk of second primary malignancies among patients with carcinoid of the lung.
    Lung Cancer. 2021;151:5-7.
    PubMed     Abstract available

  247. XIONG L, Li X, Chen D, Li S, et al
    GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
    Lung Cancer. 2021;151:104-105.

  248. TAKAHASHI T, Umeguchi H, Tateishi A, Yoshida T, et al
    Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib.
    Lung Cancer. 2021;151:1-4.
    PubMed     Abstract available

  249. BLONS H, Oudart JB, Merlio JP, Debieuvre D, et al
    PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project.
    Lung Cancer. 2021;151:69-75.
    PubMed     Abstract available

  250. WANG H, Shan Q, Guo J, Han X, et al
    PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab.
    Lung Cancer. 2021;151:76-83.
    PubMed     Abstract available

    December 2020
  251. DURHAM DD, Croswell JM, Marcus PM
    Do competing causes of mortality contribute to overdiagnosis in lung cancer screening?
    Lung Cancer. 2020;153:21-24.
    PubMed     Abstract available

  252. ABBAR B, De Castelbajac V, Gougis P, Assoun S, et al
    Definitions, outcomes, and management of hyperprogression in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors.
    Lung Cancer. 2020;152:109-118.
    PubMed     Abstract available

  253. LOBEFARO R, Viscardi G, Di Liello R, Massa G, et al
    Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.
    Lung Cancer. 2020;152:165-173.
    PubMed     Abstract available

  254. RONDEN MI, Bahce I, Hashemi SMS, Dickhoff C, et al
    Factors influencing multi-disciplinary tumor board recommendations in stage III non-small cell lung cancer.
    Lung Cancer. 2020;152:149-156.
    PubMed     Abstract available

    Lung cancer outcomes: Are BMI and race clinically relevant?
    Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30749.

  256. SHIBATA Y, Matsumoto S, Yoh K, Goto K, et al
    Evaluation of variant frequency in SARS-CoV-2 infection-related genes utilizing lung cancer genomic database.
    Lung Cancer. 2020 Dec 23. pii: S0169-5002(20)30733.

  257. CASIRAGHI M, Sedda G, Del Signore E, Piperno G, et al
    Surgery for small cell lung cancer: When and how.
    Lung Cancer. 2020;152:71-77.
    PubMed     Abstract available

  258. MATSUURA Y, Ichinose J, Nakao M, Ninomiya H, et al
    Outcomes of nodal upstaging comparing video-assisted thoracoscopic surgery versus open thoracotomy for lung cancer.
    Lung Cancer. 2020;152:78-85.
    PubMed     Abstract available

  259. DE MARINIS F, Laktionov KK, Poltoratskiy A, Egorova I, et al
    Afatinib in EGFR TKI-naive patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
    Lung Cancer. 2020;152:127-134.
    PubMed     Abstract available

  260. THOMAS PA, Couderc AL, Boulate D, Greillier L, et al
    Early-stage non-small cell lung cancer beyond life expectancy: Still not too old for surgery?
    Lung Cancer. 2020;152:86-93.
    PubMed     Abstract available

  261. PENG W, Pu X, Jiang M, Wang J, et al
    Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
    Lung Cancer. 2020;152:66-70.
    PubMed     Abstract available

  262. YANG X, Man J, Chen H, Zhang T, et al
    Temporal trends of the lung cancer mortality attributable to smoking from 1990 to 2017: A global, regional and national analysis.
    Lung Cancer. 2020;152:49-57.
    PubMed     Abstract available

  263. TAKAMORI S, Takada K, Shimokawa M, Matsubara T, et al
    Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Lung Cancer. 2020;152:27-33.
    PubMed     Abstract available

  264. JIANG M, Fares AF, Shepshelovich D, Yang P, et al
    The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) patients.
    Lung Cancer. 2020;152:58-65.
    PubMed     Abstract available

  265. YANG GJ, Li J, Xu HY, Sun Y, et al
    Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.
    Lung Cancer. 2020;152:39-48.
    PubMed     Abstract available

  266. VIGARIOS E, Rabeau A, Mazieres J, Sibaud V, et al
    Stomatitis associated with osimertinib in advanced lung cancer treatment: Characterization and implications for management.
    Lung Cancer. 2020 Dec 4. pii: S0169-5002(20)30714.

  267. MOLDAVER D, Hurry M, Evans WK, Cheema PK, et al
    A reply to "Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model".
    Lung Cancer. 2020 Dec 2. pii: S0169-5002(20)30691.

  268. MI J, Xu Q, Lizaso A, Zhang Y, et al
    A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung Cancer. 2020;150:259-260.

  269. LIU L, Xu Q, Lizaso A, Zhang Y, et al
    A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".
    Lung Cancer. 2020;150:254-255.

  270. LI X, Wang R, Wang L
    MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung Cancer. 2020;150:256-258.

  271. LI X, Wang L, Yu J
    ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis.
    Lung Cancer. 2020;150:252-253.

    November 2020
  272. ELFVING H, Brostrom E, Moens LNJ, Almlof J, et al
    Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer.
    Lung Cancer. 2020;151:53-59.
    PubMed     Abstract available

  273. MCCANN B, Muhr R, O'Rourke N, Milroy R, et al
    ADVANCE-1: An adapted collaborative benchmarking approach in centre-based lung cancer care.
    Lung Cancer. 2020;151:44-52.
    PubMed     Abstract available

  274. LU S, Wang J, Cheng Y, Mok T, et al
    Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078).
    Lung Cancer. 2020;152:7-14.
    PubMed     Abstract available

  275. GARON EB, Kim JS, Govindan R
    Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL.
    Lung Cancer. 2020;151:25-29.
    PubMed     Abstract available

  276. YAMAMOTO N, Seto T, Nishio M, Goto K, et al
    Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study.
    Lung Cancer. 2020;151:20-24.
    PubMed     Abstract available

  277. ARAKAWA S, Yoshida T, Shirasawa M, Takayanagi D, et al
    RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient.
    Lung Cancer. 2020 Nov 20. pii: S0169-5002(20)30690.

  278. LEE Y, Joo J, Lee YJ, Lee EK, et al
    Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer.
    Lung Cancer. 2020;151:8-15.
    PubMed     Abstract available

  279. SONI S, Rastogi A, Prasad KT, Behera D, et al
    Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort.
    Lung Cancer. 2020;151:16-19.
    PubMed     Abstract available

  280. TSITSIAS T, Okiror L, Veres L, King J, et al
    New N1/N2 classification and lobe specific lymphatic drainage: Impact on survival in patients with non-small cell lung cancer treated with surgery.
    Lung Cancer. 2020 Nov 16. pii: S0169-5002(20)30680.
    PubMed     Abstract available

  281. WAKUDA K, Yabe M, Kodama H, Nishioka N, et al
    Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression.
    Lung Cancer. 2020 Nov 15. pii: S0169-5002(20)30684.
    PubMed     Abstract available

  282. WANG M, Zhang D, Wang G, Xia J, et al
    HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient.
    Lung Cancer. 2020 Nov 13. pii: S0169-5002(20)30679.

  283. JOOSTEN PJM, Dickhoff C, van der Noort V, Klomp HM, et al
    Is pneumonectomy justifiable for patients with a locoregional recurrence or persistent disease after curative intent chemoradiotherapy for locally advanced non-small cell lung cancer?
    Lung Cancer. 2020;150:209-215.
    PubMed     Abstract available

  284. ZHOU Y, Wang B, Qu J, Yu F, et al
    Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors.
    Lung Cancer. 2020;150:178-185.
    PubMed     Abstract available

  285. VICKERS AJ, Frese K, Galvin M, Carter M, et al
    Brief report on the clinical characteristics of patients whose samples generate small cell lung cancer circulating tumour cell derived explants.
    Lung Cancer. 2020;150:216-220.
    PubMed     Abstract available

  286. GASSA A, Fassunke J, Schueten S, Kuhlmann L, et al
    Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence.
    Lung Cancer. 2020 Nov 5. pii: S0169-5002(20)30670.
    PubMed     Abstract available

  287. WU YL, Shi Y, Tan DSW, Xiaoqing L, et al
    Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
    Lung Cancer. 2020;150:240-246.
    PubMed     Abstract available

  288. LI JJN, Karim K, Sung M, Le LW, et al
    Tobacco exposure and immunotherapy response in PD-L1 positive lung cancer patients.
    Lung Cancer. 2020;150:159-163.
    PubMed     Abstract available

  289. BISHNOI R, Shah C, Blaes A, Bian J, et al
    Cardiovascular toxicity in patients treated with immunotherapy for metastatic non-small cell lung cancer: A SEER-medicare study: CVD outcomes with the use of ICI in mNSCLC.
    Lung Cancer. 2020;150:172-177.
    PubMed     Abstract available

  290. GRIESINGER F, Eberhardt W, Nusch A, Reiser M, et al
    Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
    Lung Cancer. 2020 Nov 2. pii: S0169-5002(20)30663.
    PubMed     Abstract available

    October 2020
  291. YUN JK, Park I, Kim HR, Choi YS, et al
    Long-term outcomes of video-assisted thoracoscopic lobectomy for clinical N1 non-small cell lung cancer: A propensity score-weighted comparison with open thoracotomy.
    Lung Cancer. 2020;150:201-208.
    PubMed     Abstract available

  292. BERSANELLI M, Buti S, Giannarelli D, Leonetti A, et al
    Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
    Lung Cancer. 2020;150:123-131.
    PubMed     Abstract available

  293. FAEHLING M, Schumann C, Christopoulos P, Hoffknecht P, et al
    Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP).
    Lung Cancer. 2020;150:114-122.
    PubMed     Abstract available

  294. ZENG C, Gao Y, Xiong J, Lu J, et al
    Tumor-infiltrating CD8(+) T cells in ALK-positive lung cancer are functionally impaired despite the absence of PD-L1 on tumor cells.
    Lung Cancer. 2020;150:139-144.
    PubMed     Abstract available

  295. YOTSUKURA M, Asamura H, Suzuki S, Asakura K, et al
    Corrigendum to "Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma" [Lung Cancer 145 (2020) 158-166].
    Lung Cancer. 2020 Oct 13. pii: S0169-5002(20)30639.

  296. SUBBIAH V, Paz-Ares L, Besse B, Moreno V, et al
    Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
    Lung Cancer. 2020;150:90-96.
    PubMed     Abstract available

  297. WANG L, Ruan M, Lei B, Yan H, et al
    The potential of (18)F-FDG PET/CT in predicting PDL1 expression status in pulmonary lesions of untreated stage IIIB-IV non-small-cell lung cancer.
    Lung Cancer. 2020;150:44-52.
    PubMed     Abstract available

  298. ZENG J, Mao WM, Chen QX, Luo TB, et al
    Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
    Lung Cancer. 2020;150:164-171.
    PubMed     Abstract available

  299. GARCIA-CAMPELO R, Arrieta O, Massuti B, Rodriguez-Abreu D, et al
    Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
    Lung Cancer. 2020;150:62-69.
    PubMed     Abstract available

  300. INAGAKI Y, Tamiya A
    Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'.
    Lung Cancer. 2020;148:179-180.

    September 2020
  301. SHAO D, Cheng Y, Yuan ZS, Jiang BY, et al
    Value of interim (18)F-FDG PET/CT for predicting progression-free survival in stage B/IV EGFR-mutant non-small-cell lung cancer patients with EGFR-TKI therapy.
    Lung Cancer. 2020;149:137-143.
    PubMed     Abstract available

  302. TAO H, Shi L, Zhou A, Li H, et al
    Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2020;149:154-161.
    PubMed     Abstract available

  303. ZHANG L, Yip R, Jirapatnakul A, Li M, et al
    Lung cancer screening intervals based on cancer risk.
    Lung Cancer. 2020;149:113-119.
    PubMed     Abstract available

  304. TAKEDA-MIYATA N, Konishi E, Tanaka T, Shimomura M, et al
    Prognostic significance of spread through air spaces in pulmonary metastases from colorectal cancer.
    Lung Cancer. 2020;149:61-67.
    PubMed     Abstract available

  305. FUKUMOTO K, Mori S, Shintani Y, Okami J, et al
    Impact of the preoperative body mass index on the postoperative outcomes in patients with completely resected non-small cell lung cancer: A retrospective analysis of 16,503 cases in a Japanese Lung Cancer Registry Study.
    Lung Cancer. 2020;149:120-129.
    PubMed     Abstract available

  306. GOLDMAN JW, Garassino MC, Chen Y, Ozguroglu M, et al
    Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.
    Lung Cancer. 2020;149:46-52.
    PubMed     Abstract available

  307. REISSIG TM, Sara L, Ting S, Reis H, et al
    ERK phosphorylation as a marker of RAS activity and its prognostic value in non-small cell lung cancer.
    Lung Cancer. 2020;149:10-16.
    PubMed     Abstract available

  308. LIU X, Hong L, Nilsson M, Hubert SM, et al
    Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer.
    Lung Cancer. 2020;149:33-40.
    PubMed     Abstract available

  309. LI J, Wang Y, Zhang B, Xu J, et al
    Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing.
    Lung Cancer. 2020;149:17-22.
    PubMed     Abstract available

  310. ALBORELLI I, Bratic Hench I, Chijioke O, Prince SS, et al
    Robust assessment of tumor mutational burden in cytological specimens from lung cancer patients.
    Lung Cancer. 2020;149:84-89.
    PubMed     Abstract available

  311. VOONG KR, Naidoo J
    Radiation pneumonitis after definitive chemoradiation and durvalumab for non-small cell lung cancer.
    Lung Cancer. 2020 Sep 5. pii: S0169-5002(20)30596.

  312. BERGHMANS T, Lievens Y, Aapro M, Baird AM, et al
    European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer.
    Lung Cancer. 2020;150:221-239.
    PubMed     Abstract available

    August 2020
  313. BAUM P, Diers J, Haag J, Klotz L, et al
    Nationwide effect of high procedure volume in lung cancer surgery on in-house mortality in Germany.
    Lung Cancer. 2020;149:78-83.
    PubMed     Abstract available

  314. CHU X, Zhao J, Zhou J, Zhou F, et al
    Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Lung Cancer. 2020;150:76-82.
    PubMed     Abstract available

  315. CHRISTOPOULOS P, Kirchner M, Roeper J, Saalfeld F, et al
    Risk stratification of EGFR(+) lung cancer diagnosed with panel-based next-generation sequencing.
    Lung Cancer. 2020;148:105-112.
    PubMed     Abstract available

  316. SUDA K, Murakami I, Obata K, Sakai K, et al
    Spatial heterogeneity of acquired resistance mechanisms to 1st/2nd generation EGFR tyrosine kinase inhibitors in lung cancer.
    Lung Cancer. 2020;148:100-104.
    PubMed     Abstract available

  317. ISMAIL RK, Schramel FMNH, van Dartel M, Hilarius DL, et al
    The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients.
    Lung Cancer. 2020;149:68-77.
    PubMed     Abstract available

  318. ANG L, Chan CPY, Yau WP, Seow WJ, et al
    Association between family history of lung cancer and lung cancer risk: a systematic review and meta-analysis.
    Lung Cancer. 2020;148:129-137.
    PubMed     Abstract available

  319. YAMAMOTO M, Serizawa T, Sato Y, Higuchi Y, et al
    Stereotactic radiosurgery for brain metastases: A retrospective cohort study comparing treatment results between two lung cancer patient age groups, 75 years or older vs 65-74 years.
    Lung Cancer. 2020;149:103-112.
    PubMed     Abstract available

  320. VAN VEGGEL B, de Langen AJ
    A reply to "Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer".
    Lung Cancer. 2020 Aug 8. pii: S0169-5002(20)30555.

  321. RECK M, Syrigos K, Miliauskas S, Zochbauer-Muller S, et al
    Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy.
    Lung Cancer. 2020;148:159-165.
    PubMed     Abstract available

  322. WADDLE MR, Ko SJ, May J, Kaleem T, et al
    Improving identification of candidates for lung cancer screening in a high risk population.
    Lung Cancer. 2020;148:79-85.
    PubMed     Abstract available

  323. MADISON R, Schrock AB, Castellanos E, Gregg JP, et al
    Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
    Lung Cancer. 2020;148:69-78.
    PubMed     Abstract available

  324. SURYAVANSHI M, Jaipuria J, Panigrahi MK, Goyal N, et al
    CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer.
    Lung Cancer. 2020;148:33-39.
    PubMed     Abstract available

  325. MARCHIONI A, Andrisani D, Tonelli R, Piro R, et al
    Integrated intErventional bronchoscopy in the treatment of locally adVanced non-small lung cancER with central Malignant airway Obstructions: a multicentric REtrospective study (EVERMORE).
    Lung Cancer. 2020;148:40-47.
    PubMed     Abstract available

  326. CHANG HL, Wei PJ, Wu KL, Huang HL, et al
    Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic.
    Lung Cancer. 2020;146:376-377.

  327. WANG K, Liu Y, Hu T, Liu Y, et al
    The treatment and outcome of a pulmonary sarcomatoid carcinoma patient infected with SARS-CoV-2.
    Lung Cancer. 2020;146:373-375.

    July 2020
  328. BARTLETT EC, Kemp SV, Ridge CA, Desai SR, et al
    Baseline Results of the West London lung cancer screening pilot study - Impact of mobile scanners and dual risk model utilisation.
    Lung Cancer. 2020;148:12-19.
    PubMed     Abstract available

  329. ROJO F, Corassa M, Mavroudis D, Oz AB, et al
    International real-world study of DLL3 expression in patients with small cell lung cancer.
    Lung Cancer. 2020;147:237-243.
    PubMed     Abstract available

  330. YOUNG K, Jiang H, Marquez M, Yeung J, et al
    Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;147:214-220.
    PubMed     Abstract available

  331. VAD-NIELSEN J, Meldgaard P, Sorensen BS, Nielsen AL, et al
    Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients.
    Lung Cancer. 2020;147:244-251.
    PubMed     Abstract available

  332. YANG G, Xu H, Yang L, Xu F, et al
    Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Lung Cancer. 2020;147:229-236.
    PubMed     Abstract available

  333. ZHENG J, Cao H, Li Y, Rao C, et al
    Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
    Lung Cancer. 2020;147:130-136.
    PubMed     Abstract available

  334. FAN Y, Chen J, Zhou C, Wang H, et al
    Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
    Lung Cancer. 2020;147:209-213.
    PubMed     Abstract available

  335. VARLOTTO JM, Voland R, DeCamp MM, Rava P, et al
    The rates of second lung cancers and the survival of surgically-resected second primary lung cancers in patients undergoing resection of an initial primary lung cancer.
    Lung Cancer. 2020;147:115-122.
    PubMed     Abstract available

  336. BEN DORI S, Aizic A, Sabo E, Hershkovitz D, et al
    Spatial heterogeneity of PD-L1 expression and the risk for misclassification of PD-L1 immunohistochemistry in non-small cell lung cancer.
    Lung Cancer. 2020;147:91-98.
    PubMed     Abstract available

  337. SVEDBERG A, Bjorn N, Sigurgeirsson B, Pradhananga S, et al
    Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing.
    Lung Cancer. 2020;147:106-114.
    PubMed     Abstract available

  338. TOUMAZIS I, Bastani M, Han SS, Plevritis SK, et al
    Risk-Based lung cancer screening: A systematic review.
    Lung Cancer. 2020;147:154-186.
    PubMed     Abstract available

  339. JIA XH, Xu H, Geng LY, Jiao M, et al
    Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis.
    Lung Cancer. 2020;147:143-153.
    PubMed     Abstract available

  340. SUH JW, Jeong YH, Cho A, Kim DJ, et al
    Corrigendum to "Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer" [Lung Cancer 142 (2020) 28-33].
    Lung Cancer. 2020 Jul 8. pii: S0169-5002(20)30485.

  341. SUN C, Anraku M, Kawahara T, Karasaki T, et al
    Prognostic significance of low pectoralis muscle mass on preoperative chest computed tomography in localized non-small cell lung cancer after curative-intent surgery.
    Lung Cancer. 2020;147:71-76.
    PubMed     Abstract available

  342. HAENTSCHEL M, Boeckeler M, Ehab A, Wagner R, et al
    A reply to "A modern approach to Advanced Non-Small Cell Lung Cancer: Minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing".
    Lung Cancer. 2020 Jul 3. pii: S0169-5002(20)30515.

  343. REMON J, Nadal E, Domine M, Ruffinelli J, et al
    Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group.
    Lung Cancer. 2020;147:83-90.
    PubMed     Abstract available

  344. WANG Q, Li X, Ren S, Su C, et al
    HOTAIR induces EGFR-TKIs resistance in non-small cell lung cancer through epithelial-mesenchymal transition.
    Lung Cancer. 2020;147:99-105.
    PubMed     Abstract available

  345. DI NOIA V, D'Aveni A, Squadroni M, Beretta GD, et al
    Immune checkpoint inhibitors in SARS-CoV-2 infected cancer patients: the spark that ignites the fire?
    Lung Cancer. 2020;145:208-210.

  346. CHEN H, Louie AV
    High risk, same reward?
    Lung Cancer. 2020;145:221.

  347. BALDINI E, Tibaldi C
    A reply to "Immune related adverse events and response to immunotherapy: focus on corticosteroids."
    Lung Cancer. 2020;145:226.

  348. INDINI A, Rijavec E, Grossi F
    Immune related adverse events and response to immunotherapy: Focus on corticosteroids.
    Lung Cancer. 2020;145:225.

    June 2020
  349. CORSINI EM, Wang Q, Tran HT, Mitchell KG, et al
    Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively.
    Lung Cancer. 2020;146:303-309.
    PubMed     Abstract available

  350. CUI W, Franchini F, Alexander M, Officer A, et al
    Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer.
    Lung Cancer. 2020;146:310-317.
    PubMed     Abstract available

  351. SUNG JH, Brown MC, Perez-Cosio A, Pratt L, et al
    Acceptability and accuracy of patient-reported outcome measures (PROMs) for surveillance of breathlessness in routine lung cancer care: A mixed-method study.
    Lung Cancer. 2020;147:1-11.
    PubMed     Abstract available

  352. GACHECHILADZE M, Skarda J, Skanderova D, Uberall I, et al
    Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma.
    Lung Cancer. 2020;147:30-38.
    PubMed     Abstract available

  353. CHEN C, Wang W, Yu Z, Tian S, et al
    Combination of computed tomography-guided iodine-125 brachytherapy and bronchial arterial chemoembolization for locally advanced stage III non-small cell lung cancer after failure of concurrent chemoradiotherapy.
    Lung Cancer. 2020;146:290-296.
    PubMed     Abstract available

  354. SOMMER MS, Vibe-Petersen J, Staerkind MB, Langer SW, et al
    Early initiated postoperative rehabilitation enhances quality of life in patients with operable lung cancer: Secondary outcomes from a randomized trial.
    Lung Cancer. 2020;146:285-289.
    PubMed     Abstract available

  355. LU S, Chen G, Sun Y, Sun S, et al
    A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer - The FALUCA study.
    Lung Cancer. 2020;146:252-262.
    PubMed     Abstract available

  356. HURKMANS DP, Tamminga M, van Es B, Peters T, et al
    Molecular data show conserved DNA locations distinguishing lung cancer subtypes and regulation of immune genes.
    Lung Cancer. 2020;146:341-349.
    PubMed     Abstract available

  357. CHEN LN, Spivack J, Cao T, Saqi A, et al
    Characteristics and outcomes of lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;146:297-302.
    PubMed     Abstract available

  358. WANG Z, Zhao J, Ma Z, Cui J, et al
    A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients.
    Lung Cancer. 2020;147:259-268.
    PubMed     Abstract available

  359. KOBAYASHI K, Soejima K, Fukunaga K, Shintani Y, et al
    Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database.
    Lung Cancer. 2020;146:236-243.
    PubMed     Abstract available

  360. WANG W, Cheng G, Zhang G, Song Z, et al
    Evaluation of a new diagnostic immunohistochemistry approach for ROS1 rearrangement in non-small cell lung cancer.
    Lung Cancer. 2020;146:224-229.
    PubMed     Abstract available

  361. GAGNE A, Orain M, Ionescu D, Tsao MS, et al
    Comprehensive assessment of PD-L1 immunohistochemistry on paired tissue and cytology specimens from non-small cell lung cancer.
    Lung Cancer. 2020;146:276-284.
    PubMed     Abstract available

  362. NICOSIA L, Di Muzio J, Agolli L, Alongi F, et al
    What is the role of reirradiation in the management of locoregionally relapsed non small-cell lung cancer?
    Lung Cancer. 2020;146:263-275.
    PubMed     Abstract available

  363. HUANG M, Insinga RP, Burke T, Zhang Y, et al
    In response to She et al., "Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater".
    Lung Cancer. 2020 Jun 17. pii: S0169-5002(20)30489.

  364. LEI Y, Feng H, Qiang H, Shang Z, et al
    Clinical characteristics and prognostic factors of surgically resected combined small cell lung cancer: a retrospective study.
    Lung Cancer. 2020;146:244-251.
    PubMed     Abstract available

  365. LU M, Hu C, Wu F, Shu L, et al
    MiR-320a is associated with cisplatin resistance in lung adenocarcinoma and its clinical value in non-small cell lung cancer: A comprehensive analysis based on microarray data.
    Lung Cancer. 2020;147:193-197.
    PubMed     Abstract available

  366. STAHEL RA, Curioni-Fontecedro A, Rohrmann S, Dafni U, et al
    Survival outcome of non-small cell lung cancer patients: Comparing results between the database of the Comprehensive Cancer Center Zurich and the Epidemiological Cancer Registry Zurich and Zug.
    Lung Cancer. 2020;146:217-223.
    PubMed     Abstract available

  367. IGAWA S, Naoki K, Shintani Y, Sekine I, et al
    Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry.
    Lung Cancer. 2020;146:160-164.
    PubMed     Abstract available

  368. MENG P, Koopman B, Kok K, Ter Elst A, et al
    Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation.
    Lung Cancer. 2020 Jun 4. pii: S0169-5002(20)30472.
    PubMed     Abstract available

  369. FORNACON-WOOD I, Faivre-Finn C, O'Connor JPB, Price GJ, et al
    Radiomics as a personalized medicine tool in lung cancer: Separating the hope from the hype.
    Lung Cancer. 2020;146:197-208.
    PubMed     Abstract available

  370. CHEN D, Chen C, Chen Y
    Letter to the editor concerning 'Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer'.
    Lung Cancer. 2020;144:92.

    May 2020
  371. JUNG HA, Sun JM, Lee SH, Ahn JS, et al
    Ten-year patient journey of stage III non-small cell lung cancer patients: A single-center, observational, retrospective study in Korea (Realtime autOmatically updated data warehOuse in healTh care; UNIVERSE-ROOT study).
    Lung Cancer. 2020;146:112-119.
    PubMed     Abstract available

  372. JUNG HA, Noh JM, Sun JM, Lee SH, et al
    Real world data of durvalumab consolidation after chemoradiotherapy in stage III non-small-cell lung cancer.
    Lung Cancer. 2020;146:23-29.
    PubMed     Abstract available

  373. ITO M, Kanda S, Yoshida T, Okuma Y, et al
    Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
    Lung Cancer. 2020 May 30. pii: S0169-5002(20)30439.
    PubMed     Abstract available

  374. ROGADO J, Pangua C, Serrano-Montero G, Obispo B, et al
    Covid-19 and lung cancer: A greater fatality rate?
    Lung Cancer. 2020;146:19-22.
    PubMed     Abstract available

  375. YANG YM, Jang Y, Lee SH, Kang B, et al
    AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
    Lung Cancer. 2020;146:70-77.
    PubMed     Abstract available

  376. ZHENG J, Zhu Y, Sun K, Shen Q, et al
    Investigation on the prognostic impact of concurrent genomic alterations in crizotinib-treated EML4-ALK-rearranged advanced non-small cell lung cancer patients.
    Lung Cancer. 2020;146:209-216.
    PubMed     Abstract available

  377. HAN J, Tian K, Yang J, Gong Y, et al
    Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Lung Cancer. 2020;146:42-49.
    PubMed     Abstract available

  378. RECK M, Luft A, Bondarenko I, Shevnia S, et al
    A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous
    Lung Cancer. 2020;146:12-18.
    PubMed     Abstract available

  379. LIAO Z, Rivin Del Campo E, Salem A, Pang Q, et al
    Optimizing lung cancer radiation treatment worldwide in COVID-19 outbreak.
    Lung Cancer. 2020;146:230-235.
    PubMed     Abstract available

  380. TESSEMA M, Tassew DD, Yingling CM, Do K, et al
    Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients.
    Lung Cancer. 2020;146:189-196.
    PubMed     Abstract available

  381. IKEMATSU Y, Tanaka K, Toyokawa G, Ijichi K, et al
    NEUROD1 is highly expressed in extensive-disease small cell lung cancer and promotes tumor cell migration.
    Lung Cancer. 2020;146:97-104.
    PubMed     Abstract available

  382. LEAL JL, Peters G, Szaumkessel M, Leong T, et al
    NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
    Lung Cancer. 2020;146:154-159.
    PubMed     Abstract available

  383. ZHAO D, Mambetsariev I, Li H, Chen C, et al
    Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors.
    Lung Cancer. 2020;146:174-181.
    PubMed     Abstract available

  384. LAM ACL, Aggarwal R, Cheung S, Stewart EL, et al
    Predictors of participant nonadherence in lung cancer screening programs: a systematic review and meta-analysis.
    Lung Cancer. 2020;146:134-144.
    PubMed     Abstract available

  385. SHI R, Filho SNM, Li M, Fares A, et al
    BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.
    Lung Cancer. 2020;146:78-85.
    PubMed     Abstract available

  386. SHARPNACK MF, Cho JH, Johnson TS, Otterson GA, et al
    Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
    Lung Cancer. 2020;146:36-41.
    PubMed     Abstract available

  387. CHAN GH, Gwee YX, Low JL, Huang Y, et al
    Immune checkpoint inhibition for non-small cell lung cancer in patients with pulmonary tuberculosis or Hepatitis B: Experience from a single Asian centre.
    Lung Cancer. 2020;146:145-153.
    PubMed     Abstract available

    A comment on "Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms".
    Lung Cancer. 2020 May 20. pii: S0169-5002(20)30429.

  389. ZENKE Y, Niho S, Umemura S, Ishihara M, et al
    Phase I/II study of carboplatin plus weekly nab-paclitaxel in patients aged >/=75 years with squamous-cell lung cancer: TORG1322.
    Lung Cancer. 2020;146:182-188.
    PubMed     Abstract available

  390. CRENGLE S
    Comment on: Jaine et al Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand. Lung Cancer 2018, 124, 233-240. 2018/10/01. DOI: 10.1016/j.lungcan.2018.08.004.
    Lung Cancer. 2020 May 16. pii: S0169-5002(20)30377.

  391. YUN JK, Lee GD, Choi S, Kim HR, et al
    Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis.
    Lung Cancer. 2020;146:105-111.
    PubMed     Abstract available

  392. ROSSI G, Caruso D, Nosseir S, Banchelli I, et al
    A modern approach to advanced Non-Small Cell Lung Cancer: minimally-invasive procedures and in parallel multiple DNA/RNA high-throughput sequencing.
    Lung Cancer. 2020 May 14. pii: S0169-5002(20)30430.

  393. SUN F, Franks K, Murray L, Lilley J, et al
    Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: Is cardiovascular death under-reported?
    Lung Cancer. 2020;146:1-5.
    PubMed     Abstract available

  394. MORGENSZTERN D, Johnson M, Rudin CM, Rossi M, et al
    SC-002 in patients with relapsed or refractory small cell lung cancer and large cell neuroendocrine carcinoma: Phase 1 study.
    Lung Cancer. 2020;145:126-131.
    PubMed     Abstract available

  395. ISAKA T, Ito H, Nakayama H, Yokose T, et al
    Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
    Lung Cancer. 2020;145:111-118.
    PubMed     Abstract available

  396. BEAGAN JJ, Bach S, van Boerdonk RA, van Dijk E, et al
    Circulating tumor DNA analysis of EGFR-mutant non-small cell lung cancer patients receiving osimertinib following previous tyrosine kinase inhibitor treatment.
    Lung Cancer. 2020;145:173-180.
    PubMed     Abstract available

  397. QUIST M, Langer SW, Lillelund C, Winther L, et al
    Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial.
    Lung Cancer. 2020;145:76-82.
    PubMed     Abstract available

  398. DALL'OLIO FG, Maggio I, Massucci M, Mollica V, et al
    ECOG performance status >/=2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data.
    Lung Cancer. 2020;145:95-104.
    PubMed     Abstract available

  399. ROSSI D
    Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.
    Lung Cancer. 2020;145:83-84.
    PubMed     Abstract available

  400. DREVET G, Duruisseaux M, Lafitte C, Derberne M, et al
    A reply to "A comment on "Lung cancer surgical treatment after solid organ transplantation: a single center 30-year experience".
    Lung Cancer. 2020 May 6. pii: S0169-5002(20)30406.

  401. HOFMAN V, Benzaquen J, Heeke S, Lassalle S, et al
    Real-world assessment of the BRAF status in non-squamous cell lung carcinoma using VE1 immunohistochemistry: A single laboratory experience (LPCE, Nice, France).
    Lung Cancer. 2020;145:58-62.
    PubMed     Abstract available

  402. CHEN V, Iwama E, Kim IK, Giaccone G, et al
    Serum CRIPTO does not confer drug resistance against osimertinib but is an indicator of tumor burden in non-small cell lung cancer.
    Lung Cancer. 2020;145:48-57.
    PubMed     Abstract available

  403. TAKADA K, Takamori S, Yoneshima Y, Tanaka K, et al
    Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy.
    Lung Cancer. 2020;145:18-26.
    PubMed     Abstract available

  404. SERENO M, Gutierrez-Gutierrez G, Sandoval C, Falagan S, et al
    A favorable outcome of pneumonia COVID 19 in an advanced lung cancer patient with severe neutropenia: Is immunosuppression a risk factor for SARS-COV2 infection?
    Lung Cancer. 2020 May 4. pii: S0169-5002(20)30399.

    C-Myc in mucinous colloid carcinoma of the lung.
    Lung Cancer. 2020;143:93-94.

  406. SMUK G, Pajor G, Szuhai K, Morreau H, et al
    Attenuated isolated 3' signal: A highly challenging therapy relevant ALK FISH pattern in NSCLC.
    Lung Cancer. 2020;143:80-85.
    PubMed     Abstract available

  407. OKUNO T, Arakawa S, Yoshida T, Ohe Y, et al
    Efficacy of osimertinib in a patient with leptomeningeal metastasis and EGFR uncommon S768I mutation.
    Lung Cancer. 2020;143:95-96.

  408. KNEUERTZ PJ, Carbone DP, D'Souza DM, Shilo K, et al
    Prognostic value and therapeutic implications of expanded molecular testing for resected early stage lung adenocarcinoma.
    Lung Cancer. 2020;143:60-66.
    PubMed     Abstract available

  409. ZHOU Y, Jiang W, Zeng L, Mi J, et al
    A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Lung Cancer. 2020;143:55-59.
    PubMed     Abstract available

  410. SHERMAN S, Rotem O, Shochat T, Zer A, et al
    Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC).
    Lung Cancer. 2020;143:40-46.
    PubMed     Abstract available

  411. TREJO BITTAR HE, Jerome JA, Hartman D, Pantanowitz L, et al
    Prognostic significance of microscopic size in peripherally located scar-associated clinical stage I lung carcinomas.
    Lung Cancer. 2020;143:12-18.
    PubMed     Abstract available

    April 2020
  412. LIN YT, Tsai TH, Wu SG, Liu YN, et al
    Complex EGFR mutations with secondary T790M mutation confer shorter osimertinib progression-free survival and overall survival in advanced non-small cell lung cancer.
    Lung Cancer. 2020;145:1-9.
    PubMed     Abstract available

  413. THOMAS R, Chen YH, Hatabu H, Mak RH, et al
    Radiographic patterns of symptomatic radiation pneumonitis in lung cancer patients: Imaging predictors for clinical severity and outcome.
    Lung Cancer. 2020;145:132-139.
    PubMed     Abstract available

  414. DENG J, Zhao M, Wang T, She Y, et al
    A modified T categorization for part-solid lesions in Chinese patients with clinical stage I Non-small cell lung cancer.
    Lung Cancer. 2020;145:33-39.
    PubMed     Abstract available

  415. SOLOMON BJ, Kim EE, Winter M, Monti K, et al
    Ophthalmological assessment of crizotinib in advanced non-small-cell lung cancer.
    Lung Cancer. 2020;145:167-172.
    PubMed     Abstract available

  416. SCHEFFLER M, Holzem A, Kron A, Nogova L, et al
    Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
    Lung Cancer. 2020;144:40-48.
    PubMed     Abstract available

  417. LIU B, Henschke CI, Flores RM, Taioli E, et al
    Serum cotinine verification of self-reported smoking status among adults eligible for lung cancer screening in the 1999-2018 National Health and Nutrition Examination Survey.
    Lung Cancer. 2020;144:49-56.
    PubMed     Abstract available

  418. POPAT S, Grohe C, Corral J, Reck M, et al
    Anti-angiogenic agents in the age of resistance to immune checkpoint inhibitors: Do they have a role in non-oncogene-addicted non-small cell lung cancer?
    Lung Cancer. 2020;144:76-84.
    PubMed     Abstract available

  419. DE RUITER JC, Heineman DJ, Daniels JM, van Diessen JN, et al
    The role of surgery for stage I non-small cell lung cancer in octogenarians in the era of stereotactic body radiotherapy in the Netherlands.
    Lung Cancer. 2020;144:64-70.
    PubMed     Abstract available

  420. BREADNER D, Blanchette P, Shanmuganathan S, Boldt RG, et al
    Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis.
    Lung Cancer. 2020;144:57-63.
    PubMed     Abstract available

  421. JAINE R, Kvizhinadze G, Nair N, Blakely T, et al
    Cost-effectiveness of a low-dose computed tomography screening programme for lung cancer in New Zealand.
    Lung Cancer. 2020 Apr 18. pii: S0169-5002(20)30337.
    PubMed     Abstract available

  422. GOFFIN JR
    Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model.
    Lung Cancer. 2020 Apr 4. pii: S0169-5002(20)30351.

  423. ESCOIN-PEREZ C, Blasco S, Juan-Vidal O
    Immune checkpoint inhibitors in special populations. A focus on advanced lung cancer patients.
    Lung Cancer. 2020;144:1-9.
    PubMed     Abstract available

  424. THAI AA, Stuart E, Te Marvelde L, Milne RL, et al
    Reply to the letter-to-the editor "Hospital volume and the case for centralisation of surgical services".
    Lung Cancer. 2020;142:140-141.

  425. STIRLING R, Stenger M, Zalcberg J
    Comment on: 'Hospital lung surgery volume and patient outcomes'.
    Lung Cancer. 2020;142:138-139.

  426. MOODLEY S, Lian EY, Crupi MJF, Hyndman BD, et al
    RET isoform-specific interaction with scaffold protein Ezrin promotes cell migration and chemotaxis in lung adenocarcinoma.
    Lung Cancer. 2020;142:123-131.
    PubMed     Abstract available

  427. SALA L, Mancin M, Pastore A, Seminati D, et al
    Aplastic anemia in a patient with advanced lung adenocarcinoma during first line osimertinib: A case report and literature review.
    Lung Cancer. 2020;142:120-122.
    PubMed     Abstract available

  428. CHEN HF, Wang WX, Xu CW, Huang LC, et al
    A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Lung Cancer. 2020;142:59-62.
    PubMed     Abstract available

  429. ZUCALI PA, Perrino M, De Vincenzo F, Giordano L, et al
    A phase II study of the combination of gemcitabine and imatinib mesylate in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Lung Cancer. 2020;142:132-137.
    PubMed     Abstract available

  430. CHAN OSH, Lam KC, Li JYC, Choi FPT, et al
    ATOM: A phase II study to assess efficacy of preemptive local ablative therapy to residual oligometastases of NSCLC after EGFR TKI.
    Lung Cancer. 2020;142:41-46.
    PubMed     Abstract available

  431. SUH JW, Jeong YH, Cho A, Kim DJ, et al
    Stepwise flowchart for decision making on sublobar resection through the estimation of spread through air space in early stage lung cancer(1).
    Lung Cancer. 2020;142:28-33.
    PubMed     Abstract available

  432. AN N, Leng X, Wang X, Sun Y, et al
    Survival comparison of Three histological subtypes of lung squamous cell carcinoma: A population-based propensity score matching analysis.
    Lung Cancer. 2020;142:13-19.
    PubMed     Abstract available

    March 2020
  433. FRUH M, Panje CM, Reck M, Blackhall F, et al
    Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.
    Lung Cancer. 2020;146:6-11.
    PubMed     Abstract available

  434. VERONESI G, Navone N, Novellis P, Dieci E, et al
    Favorable incremental cost-effectiveness ratio for lung cancer screening in Italy.
    Lung Cancer. 2020;143:73-79.
    PubMed     Abstract available

  435. BOYSEN FYNBOE EBERT E, McCulloch T, Holmskov Hansen K, Linnet H, et al
    Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
    Lung Cancer. 2020;143:67-72.
    PubMed     Abstract available

  436. MA L, Zhang Q, Dong Y, Li H, et al
    SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30347.

  437. YANG G, Li J, Xu H, Yang Y, et al
    EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Lung Cancer. 2020 Mar 18. pii: S0169-5002(20)30344.
    PubMed     Abstract available

  438. PETERS S, Shaw AT, Besse B, Felip E, et al
    Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
    Lung Cancer. 2020;144:10-19.
    PubMed     Abstract available

  439. SHEINSON D, Wong WB, Wu N, Mansfield AS, et al
    Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer.
    Lung Cancer. 2020;143:86-92.
    PubMed     Abstract available

  440. ITO M, Miyata Y, Tsutani Y, Ito H, et al
    Positive EGFR mutation status is a risk of recurrence in pN0-1 lung adenocarcinoma when combined with pathological stage and histological subtype: A retrospective multi-center analysis.
    Lung Cancer. 2020;141:107-113.
    PubMed     Abstract available

  441. GOSNEY JR, Boothman AM, Ratcliffe M, Kerr KM, et al
    Cytology for PD-L1 testing: A systematic review.
    Lung Cancer. 2020;141:101-106.
    PubMed     Abstract available

  442. LI C, Shen Y, Hu F, Chu T, et al
    Micropapillary pattern is associated with the development of brain metastases and the reduction of survival time in EGFR-mutation lung adenocarcinoma patients with surgery.
    Lung Cancer. 2020;141:72-77.
    PubMed     Abstract available

  443. ZHAO J, Lin G, Zhuo M, Fan Z, et al
    Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.
    Lung Cancer. 2020;141:114-118.
    PubMed     Abstract available

    February 2020
  444. PERTEJO-FERNANDEZ A, Ricciuti B, Hammond SP, Marty FM, et al
    Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection.
    Lung Cancer. 2020 Feb 24. pii: S0169-5002(20)30310.
    PubMed     Abstract available

  445. WANG F, Qin J, Xie F, Wu Q, et al
    Transformation of EML4-ALK fusion-positive adenocarcinoma into squamous cell carcinoma in association with acquired resistance to crizotinib.
    Lung Cancer. 2020;140:118-120.

  446. LAM WS, Creaney J, Chen FK, Chin WL, et al
    A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lung Cancer. 2020;140:87-92.
    PubMed     Abstract available

  447. WU H, Dong S, Li X, Shi L, et al
    Clinical utility of dual-energy CT used as an add-on to 18F FDG PET/CT in the preoperative staging of resectable NSCLC with suspected single osteolytic metastases.
    Lung Cancer. 2020;140:80-86.
    PubMed     Abstract available

  448. REALE ML, Chiari R, Tiseo M, Vitiello F, et al
    Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
    Lung Cancer. 2020;140:71-79.
    PubMed     Abstract available

  449. BALDINI E, Lunghi A, Cortesi E, Turci D, et al
    Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
    Lung Cancer. 2020;140:59-64.
    PubMed     Abstract available

  450. GIBERT J, Clave S, Hardy-Werbin M, Taus A, et al
    Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
    Lung Cancer. 2020;140:42-45.
    PubMed     Abstract available

  451. SANDS JM, Nguyen T, Shivdasani P, Sacher AG, et al
    Next-generation sequencing informs diagnosis and identifies unexpected therapeutic targets in lung squamous cell carcinomas.
    Lung Cancer. 2020;140:35-41.
    PubMed     Abstract available

  452. EDAHIRO R, Shiroyama T, Hijiki S, Nojima S, et al
    Severe myocarditis with slight lymphocytic infiltration after nivolumab treatment.
    Lung Cancer. 2020;140:116-117.

  453. SHOJI S, Watanabe S, Takamura K, Umezu H, et al
    First-line osimertinib treatment in patients with lung squamous cell carcinoma harboring active epidermal growth factor receptor mutations.
    Lung Cancer. 2020;140:113-115.

    January 2020
  454. ZHOU F, Zhao W, Chen X, Zhang J, et al
    Response to the combination of dabrafenib, trametinib and osimertinib in a patient with EGFR-mutant NSCLC harboring an acquired BRAF(V600E) mutation.
    Lung Cancer. 2020;139:219-220.

  455. ZELTSMAN M, Dozier J, Vaghjiani RG, Poch A, et al
    Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity.
    Lung Cancer. 2020;139:68-72.
    PubMed     Abstract available

  456. PINSKY P, Gierada DS
    Long-term cancer risk associated with lung nodules observed on low-dose screening CT scans.
    Lung Cancer. 2020;139:179-184.
    PubMed     Abstract available

  457. MIYAKE N, Ochi N, Yamane H, Fukazawa T, et al
    Targeting ROR1 in combination with pemetrexed in malignant mesothelioma cells.
    Lung Cancer. 2020;139:170-178.
    PubMed     Abstract available

  458. WIESWEG M, Herold T, Metzenmacher M, Eberhardt WE, et al
    Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
    Lung Cancer. 2020;139:165-168.
    PubMed     Abstract available

  459. YANG S, Mao S, Li X, Zhao C, et al
    Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC.
    Lung Cancer. 2020;139:133-139.
    PubMed     Abstract available

  460. STOCKHAMMER P, Ploenes T, Theegarten D, Schuler M, et al
    Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Lung Cancer. 2020;139:124-132.
    PubMed     Abstract available

  461. ZHANG JT, Li Y, Yan LX, Zhu ZF, et al
    Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study.
    Lung Cancer. 2020;139:118-123.
    PubMed     Abstract available

  462. WANG B, Tang Y, Chen Y, Hamal P, et al
    Joint use of the radiomics method and frozen sections should be considered in the prediction of the final classification of peripheral lung adenocarcinoma manifesting as ground-glass nodules.
    Lung Cancer. 2020;139:103-110.
    PubMed     Abstract available

  463. CHEN X, Pang Z, Wang Y, Bie F, et al
    The role of surgery for atypical bronchopulmonary carcinoid tumor: Development and validation of a model based on Surveillance, Epidemiology, and End Results (SEER) database.
    Lung Cancer. 2020;139:94-102.
    PubMed     Abstract available

  464. SOUSA AC, Silveira C, Janeiro A, Malveiro S, et al
    Detection of rare and novel EGFR mutations in NSCLC patients: Implications for treatment-decision.
    Lung Cancer. 2020;139:35-40.
    PubMed     Abstract available

  465. CARACENI A, Lo Dico S, Zecca E, Brunelli C, et al
    Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
    Lung Cancer. 2020;139:13-17.
    PubMed     Abstract available

  466. RIBEIRO MFSA, Alessi JVM, Oliveira LJC, Gongora ABL, et al
    Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series.
    Lung Cancer. 2020;139:9-12.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.